1
|
Giles J, Cruz M, Cobo A, Vidal C, Requena A, Remohi J, Bosch E. Corrigendum to 'Medroxyprogesterone acetate: an alternative to GnRH-antagonist in oocyte vitrification for social fertility preservation and preimplantation genetic testing for aneuploidy' Reproductive Biomedicine Online. 2023 Aug;47(2):103222. Reprod Biomed Online 2024; 48:103841. [PMID: 38262210 DOI: 10.1016/j.rbmo.2024.103841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2024]
Affiliation(s)
- J Giles
- IVIRMA Valencia; IVI Foundation.
| | - M Cruz
- IVIRMA Valencia; IVI Foundation
| | - A Cobo
- IVIRMA Valencia; IVI Foundation
| | - C Vidal
- IVIRMA Valencia; IVI Foundation
| | | | | | - E Bosch
- IVIRMA Valencia; IVI Foundation
| |
Collapse
|
2
|
Duarte AC, Fernandes BM, Bernardes M, Tenazinha C, Martins P, Mazeda C, Mendes B, Guimarães F, Gago L, Correia AM, Valido A, Silva L, Brites L, Meirinhos T, Araújo F, Nero P, Cruz M, Teixeira L, Santos MJ. Lung disease in rheumatoid arthritis: Results from a national cohort. Pulmonology 2024; 30:87-89. [PMID: 37394340 DOI: 10.1016/j.pulmoe.2023.05.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 05/19/2023] [Accepted: 05/24/2023] [Indexed: 07/04/2023] Open
Affiliation(s)
- A C Duarte
- Serviço de Reumatologia, Hospital Garcia de Orta, Avenida Torrado da Silva, 2805-267 Almada, Portugal.
| | - B M Fernandes
- Serviço de Reumatologia, Centro Hospitalar Universitário São João, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
| | - M Bernardes
- Serviço de Reumatologia, Centro Hospitalar Universitário São João, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal; Departamento de Medicina, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
| | - C Tenazinha
- Serviço de Reumatologia e Doenças Ósseas Metabólicas, Centro Hospitalar Lisboa Norte, Avenida Professor Egas Moniz, 1649-035 Lisboa, Portugal; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal
| | - P Martins
- Serviço de Reumatologia e Doenças Ósseas Metabólicas, Centro Hospitalar Lisboa Norte, Avenida Professor Egas Moniz, 1649-035 Lisboa, Portugal; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal
| | - C Mazeda
- Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Avenida Artur Ravara, 3814-501 Aveiro, Portugal
| | - B Mendes
- Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra, Praceta Prof. Mota Pinto, 3004-561 Coimbra, Portugal
| | - F Guimarães
- Serviço de Reumatologia, Unidade Local de Saúde do Alto Minho, Rua Conde de Bertiandos, 4990-041 Ponte de Lima, Portugal
| | - L Gago
- Serviço de Reumatologia, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Rua da Junqueira 126, 1349-019 Lisboa, Portugal
| | - A M Correia
- Serviço de Reumatologia, Hospital de Braga, Sete Fontes - São Victor, 4710-243 Braga, Portugal
| | - A Valido
- Serviço de Reumatologia, Unidade Local de Saúde do Litoral Alentejano, Monte do Gilbardinho, 7540-230 Santiago do Cacém, Portugal
| | - L Silva
- Serviço de Reumatologia, Centro Hospitalar de Trás-os-Montes e Alto Douro, Avenida Noruega/Lordelo, 5000-508 Vila Rela, Portugal
| | - L Brites
- Serviço de Reumatologia, Centro Hospitalar de Leiria, Rua de Santo André, 2410-197 Leiria, Portugal
| | - T Meirinhos
- Serviço de Reumatologia, Centro Hospitalar do Tâmega e Sousa, Av. do Hospital Padre Américo 210, 4564-007 Guilhufe, Portugal
| | - F Araújo
- Serviço de Reumatologia, Hospital Ortopédico de Sant`Ana, Rua de Benguela 2779-501 Parede, Portugal
| | - P Nero
- Serviço de Reumatologia, Hospital CUF Descobertas, Rua Mário Botas, 1998-018 Lisboa, Portugal
| | - M Cruz
- Serviço de Reumatologia, Centro Hospitalar de S. Francisco, Rua Fonte Cabeço d'El Rei 15, Leiria, Portugal
| | - L Teixeira
- Serviço de Reumatologia, Hospital Central do Funchal, Avenida Luís de Camões, nº 57 9004-514 Funchal, Portugal
| | - M J Santos
- Serviço de Reumatologia, Hospital Garcia de Orta, Avenida Torrado da Silva, 2805-267 Almada, Portugal; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal
| |
Collapse
|
3
|
Yin K, Whitaker L, Hojo E, McLenachan S, Walker J, McKillop G, Stubbs C, Priest L, Cruz M, Roberts N, Critchley H. Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB). Hum Reprod Open 2023; 2023:hoad021. [PMID: 37304815 PMCID: PMC10247393 DOI: 10.1093/hropen/hoad021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Revised: 03/28/2023] [Indexed: 06/13/2023] Open
Abstract
STUDY QUESTION Does application of an unbiased method for analysis of magnetic resonance (MR) images reveal any effect on uterine or fibroid volume from treatment of heavy menstrual bleeding (HMB) with three 12-week courses of the selective progesterone receptor modulator ulipristal acetate (SPRM-UPA)? SUMMARY ANSWER Application of an unbiased method for analysis of MR images showed that treatment of HMB with SPRM-UPA was not associated with a significant reduction in the volume of the uterus or in the volume of uterine fibroids. WHAT IS KNOWN ALREADY SPRM-UPA shows therapeutic efficacy for treating HMB. However, the mechanism of action (MoA) is not well understood and there have been mixed reports, using potentially biased methodology, regarding whether SPRM-UPA has an effect on the volume of the uterus and fibroids. STUDY DESIGN SIZE DURATION In a prospective clinical study (with no comparator), 19 women with HMB were treated over a period of 12 months with SPRM-UPA and uterine and fibroid size were assessed with high resolution structural MRI and stereology. PARTICIPANTS/MATERIALS SETTING METHODS A cohort of 19 women aged 38-52 years (8 with and 11 without fibroids) were treated with three 12-week courses of 5 mg SPRM-UPA given daily, with four weeks off medication in-between treatment courses. Unbiased estimates of the volume of uterus and total volume of fibroids were obtained at baseline, and after 6 and 12 months of treatment, by using the Cavalieri method of modern design-based stereology in combination with magnetic resonance imaging (MRI). MAIN RESULTS AND THE ROLE OF CHANCE Bland-Altman plots showed good intra-rater repeatability and good inter-rater reproducibility for measurement of the volume of both fibroids and the uterus. For the total patient cohort, two-way ANOVA did not show a significant reduction in the volume of the uterus after two or three treatment courses of SPRM-UPA (P = 0.51), which was also the case when the groups of women with and without fibroids were considered separately (P = 0.63). One-way ANOVA did not show a significant reduction in total fibroid volume in the eight patients with fibroids (P = 0.17). LIMITATIONS REASONS FOR CAUTION The study has been performed in a relatively small cohort of women and simulations that have subsequently been performed using the acquired data have shown that for three time points and a group size of up to 50, with alpha (Type I Error) and beta (Type II Error) set to 95% significance and 80% power, respectively, at least 35 patients would need to be recruited in order for the null hypothesis (that there is no significant reduction in total fibroid volume) to be potentially rejected. WIDER IMPLICATIONS OF THE FINDINGS The imaging protocol that we have developed represents a generic paradigm for measuring the volume of the uterus and uterine fibroids that can be readily incorporated in future studies of medical treatments of HMB. In the present study, SPRM-UPA failed to produce a significant reduction in the volume of the uterus or the total volume of fibroids (which were present in approximately half of the patients) after either two or three 12-week courses of treatment. This finding represents a new insight in respect of the management of HMB using treatment strategies that target hormone-dependence. STUDY FUNDING/COMPETING INTERESTS The UPA Versus Conventional Management of HMB (UCON) trial was funded by the EME Programme (Medical Research Council (MRC) and National Institutes of Health Research (NIHR)) (12/206/52). The views expressed in this publication are those of the authors and not necessarily those of the Medical Research Council, National Institute for Health Research, or Department of Health and Social Care.Medical Research Council (MRC) Centre grants to the Centre for Reproductive Health (CRH) (G1002033 and MR/N022556/1) are also gratefully acknowledged. H.C. has clinical research support for laboratory consumables and staff from Bayer AG and provides consultancy advice (All paid to Institution) for Bayer AG, PregLem SA, Gedeon Richter, Vifor Pharma UK Ltd, AbbVie Inc., and Myovant Sciences GmbH. H.C. has received royalties from UpToDate for an article on abnormal uterine bleeding. L.W. has received grant funding from Roche Diagnostics (Paid to Institution). All other authors have no conflicts to declare. TRIAL REGISTRATION NUMBER The study reported here is an embedded mechanism of action study (no comparator) within the UCON clinical trial (registration ISRCTN: 20426843).
Collapse
Affiliation(s)
- K Yin
- Edinburgh Imaging Facility QMRI, University of Edinburgh, Edinburgh, UK
| | - L Whitaker
- MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK
| | - E Hojo
- MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK
| | - S McLenachan
- Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK
| | - J Walker
- Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK
| | - G McKillop
- Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK
| | - C Stubbs
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - L Priest
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - M Cruz
- Departamento de Matemáticas Estadística y Computación, University of Cantabria, Santander, Spain
| | - N Roberts
- Edinburgh Imaging Facility QMRI, University of Edinburgh, Edinburgh, UK
- MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK
| | - H Critchley
- MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
4
|
Murga-Garrido SM, Ulloa-Pérez EJ, Díaz-Benítez CE, Orbe-Orihuela YC, Cornejo-Granados F, Ochoa-Leyva A, Sanchez-Flores A, Cruz M, Castañeda-Márquez AC, Plett-Torres T, Burguete García AI, Lagunas-Martínez A. Virulence Factors of the Gut Microbiome Are Associated with BMI and Metabolic Blood Parameters in Children with Obesity. Microbiol Spectr 2023; 11:e0338222. [PMID: 36786619 PMCID: PMC10101034 DOI: 10.1128/spectrum.03382-22] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Accepted: 01/29/2023] [Indexed: 02/15/2023] Open
Abstract
The development of metabolic diseases is linked to the gut microbiota. A cross-sectional study involving 45 children (6 to 12 years old) was conducted to investigate the relationship between gut microbiota and childhood obesity. Anthropometric and metabolic measurements, food-frequency questionnaires (FFQs), and feces samples were obtained. Using the body mass index (BMI) z-score, we categorized each participant as normal weight (NW), or overweight and obese (OWOB). We determined 2 dietary profiles: one with complex carbohydrates and proteins (pattern 1), and the other with saturated fat and simple carbohydrates (pattern 2). The microbial taxonomic diversity and metabolic capacity were determined using shotgun metagenomics. We found differences between both BMI groups diversity. Taxa contributing to this difference, included Eubacterium sp., Faecalibacterium prausnitzii, Dialister, Monoglobus pectinilyticus, Bifidobacterium pseudocatenulatum, Intestinibacter bartlettii, Bacteroides intestinalis, Bacteroides uniformis, and Methanobrevibacter smithii. Metabolic capacity differences found between NW and OWOB, included the amino acid biosynthesis pathway, the cofactor, carrier, and vitamin biosynthesis pathway, the nucleoside and nucleotide biosynthesis and degradation pathways, the carbohydrate-sugar degradation pathway, and the amine and polyamine biosynthesis pathway. We found significant associations between taxa such as Ruminococcus, Mitsuokella multacida, Klebsiella variicola, and Citrobacter spp., metabolic pathways with the anthropometric, metabolic, and dietary data. We also found the microbiome's lipooligosaccharide (LOS) category as differentially abundant between BMI groups. Metabolic variations emerge during childhood as a result of complex nutritional and microbial interactions, which should be explained in order to prevent metabolic illnesses in adolescence and maturity. IMPORTANCE The alteration of gut microbiome composition has been commonly observed in diseases involving inflammation, such as obesity and metabolic impairment. Inflammatory host response in the gut can be a consequence of dietary driven dysbiosis. This response is conducive to blooms of particular bacterial species, adequate to survive in an inflammatory environment by means of genetical capability of utilizing alternative nutrients. Understanding the genomic and metabolic contribution of microbiota to inflammation, including virulence factor prevalence and functional potential, will contribute to identifying modifiable early life exposures and preventive strategies associated with obesity risk in childhood.
Collapse
Affiliation(s)
- S. M. Murga-Garrido
- Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico
- PECEM (MD/PhD), Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - E. J. Ulloa-Pérez
- Department of Biostatistics, University of Washington, Seattle, Washington, USA
| | - C. E. Díaz-Benítez
- Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico
| | - Y. C. Orbe-Orihuela
- Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico
| | - F. Cornejo-Granados
- Departamento de Microbiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - A. Ochoa-Leyva
- Departamento de Microbiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - A. Sanchez-Flores
- Unidad Universitaria de Secuenciación Masiva y Bioinformática, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - M. Cruz
- Unidad de Investigación Médica en Bioquímica, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - A. C. Castañeda-Márquez
- Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico
| | - T. Plett-Torres
- PECEM (MD/PhD), Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A. I. Burguete García
- Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico
| | - A. Lagunas-Martínez
- Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico
| |
Collapse
|
5
|
Marques Reis I, Vikneswaramoorthy V, McHale G, Mullahy M, Valiakalayil J, Hallinan T, Cruz M, Nieto-Aponte L, Sibartie S. P18 Audit on compliance with the preventive measures on Clostridioides difficile. JAC Antimicrob Resist 2023. [DOI: 10.1093/jacamr/dlac133.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Abstract
Background
Clostridioides (Clostridium) difficile persists to be a significant pathogen for healthcare acquired infections. Antibiotic usage is the main cause for the overgrowth of this organism and resulting in C. difficile infections (CDI). Other factors that are known to contribute are usage of proton pump inhibitors, laxatives usage and poor compliance with infection prevention control guidance in health care settings. The audit was carried out to analyse if the local guidance is followed on recognition of new onset of diarrhoea in an inpatient.
Objectives
Analyse compliance rate with our local guidance in Mayo University Hospital to be followed when inpatient has a new onset of diarrhoea. This to include reviewing of medications; such as laxatives, proton pump inhibitor (PPI) and antibiotics; prompt isolation and CDI precautions were commenced, samples sent for testing and commencing stool chart.
Methods
The data of patients was collected by reviewing the chart and collected data was stored and analysed using excel spreadsheet.
Results
The audit was carried out over a 4 month period from 10.06.22 until 14.10.22 in 7 wards. 31 patients were recorded as having diarrhoea with 69% (n=19) female and 39% (n=12) males during their inpatient stay. Majority of the recorded patients, which is 29% (n=9) were in medical male ward. The age of the patients ranged from 24 to 92 years of age with a median of 68 years. The median number of days from the admission until onset of diarrhoea was 5. On identifying new onset of diarrhoea, 32% (n=10) had recorded documentation of medications review. Out of 31 patients, 90% (n=28) were on PPI and only 21% (n=6) of them were held, while 7% (n=2) of them had their medication reviewed and was advised to continue the PPI as for clinical indication. Ninety percent (n=28) of patients were on regular laxatives and after the onset of diarrhoea only 39% (n=11) had the laxatives held. Of all the recorded patients, 32% (n=10) of patients had documentation of medication review and 19% (n=6) were continued on antibiotics for organisms other than CDI after discussion with clinical microbiology team. Fifty-five percent (n=17) of patients were isolated after the onset of new diarrhoea while the rest remained in a shared bay as per the discussion with clinical teams, while awaiting the stool results. Sixty-five percent (n=20) had a stool culture sent for CDI testing after the onset of new diarrhoea. Of these patients, 25% (n=5) tested positive for C. difficile.
Conclusions
Compliance to local guidance should be followed more strictly to avoid development of hospital acquired CDI and to prevent outbreaks in the healthcare setting.
Collapse
Affiliation(s)
| | | | - G McHale
- Mayo University Hospital , Ireland
| | | | | | | | - M Cruz
- Mayo University Hospital , Ireland
| | | | | |
Collapse
|
6
|
Cruz M, Marroquín G, Vega-Merino P, Guzmán R, Rayo P. Study of corrosion in metallic materials during the hydrodeoxygenation of palm oil in continuous fixed-bed reactor. RMIQ 2022. [DOI: 10.24275/rmiq/mat2832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Munoz Gomez E, Orihuela L, Deka P, Klompstra L, Pathak D, Sempere-Rubio N, Sentandreu-Mano T, Mont J, Moreno-Segura N, Cruz M, Westas M, Marques-Sule E. Interests and preferences towards technology-based cardiac rehabilitation in men and women with coronary artery disease. Eur J Cardiovasc Nurs 2022. [DOI: 10.1093/eurjcn/zvac060.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Several studies have demonstrated the effectiveness of telemedicine programmes in patients with coronary artery disease (CAD). However, the development of these programmes is driven from a technical point of view and does not usually take into account the needs and expectations of patients. Thus, we found a need to study the interests and preferences towards technology-based cardiac rehabilitation (CR) in patients with CAD.
Purpose
The aim of this study was to compare the interests and preferences towards technology-based CR in men and women with CAD.
Method
A cross-sectional study was conducted. A total of 70 subjects with CAD (84.28% male) were included. Participants' interests and preferences were measured using the Technology Usage Questionnaire, which includes items on digital health and technology usage.
Results
On the one hand, men showed a greater interest in receiving CR counselling via mobile phone (p=0.022), would sign up for a free technology-based CR programme (p=0.034) and would like to receive less than 1-2 messages a week (p=0.010). On the other hand, women showed greater interest in receiving information about the different components included in the CR programme (receiving healthy meal/recipe ideas (p=0.002), reminders to take medication (p=0.039) and showed greater interest in meeting other people with heart disease (p=0.034). No differences were found by gender in type of communication that participants would like to receive through their mobile phone (p=0.154) or through the Internet (p=0.648), interest in receiving treatment through the Internet (p=0.454), interest in receiving an exercise-based CR program using virtual reality (p=0.810), nor usefulness of a virtual CR session (p=0.801).
Conclusions
In subjects with CAD, gender appears to be a determinant of interest. Men showed a greater interest in receiving CR counselling via mobile phone, would sign up for a technology-based CR programme and would like to receive fewer notifications. Women were more interested in receiving information about different components of the CR programme.
Collapse
Affiliation(s)
- E Munoz Gomez
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - L Orihuela
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - P Deka
- College of Nursing, Michigan State University , East Lansing, Michigan , United States of America
| | - L Klompstra
- Department of Medical and Health Sciences Linkoping University , Linkoping , Sweden
| | - D Pathak
- Michigan State University, Department of Statistics and Probability , East Lansing, Michigan , United States of America
| | - N Sempere-Rubio
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - T Sentandreu-Mano
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - J Mont
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - N Moreno-Segura
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - M Cruz
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - M Westas
- Department of Medical and Health Sciences Linkoping University , Linkoping , Sweden
| | - E Marques-Sule
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| |
Collapse
|
8
|
Munoz Gomez E, Moreno-Segura N, Sentandreu-Mano T, Deka P, Klompstra L, Pathak D, Sempere-Rubio N, Orihuela L, Mont J, Cruz M, Westas M, Marques-Sule E. Physical activity and technology usage performed by patients with coronary artery disease: a gender approach. Eur J Cardiovasc Nurs 2022. [DOI: 10.1093/eurjcn/zvac060.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Recent studies show that cardiac telerehabilitation, including exercise and lifestyle modification, is effective in reducing cardiovascular risk factors in patients with coronary artery disease (CAD). Thus, physical activity and technology usage of patients with CAD are important key points in order to create technology-based cardiac rehabilitation programs to improve physical patients´ condition and reduce cardiovascular risk.
Purpose
The aim of this study was to compare the physical activity and the technological usage of women and men with CAD.
Methods
A cross-sectional study in patients with CAD was performed. Sociodemographic data, physical activity (measured with the International Physical Activity Questionnaire, IPAQ) and the technology usage (measured with the Technology use subscale of the Technology Usage Questionnaire) were collected. Descriptive and inferential analyzes were performed to explore the differences between men and women with CAD.
Results
A total of 70 participants were included (84.28% men, mean age=59±8.54 years). Regarding the IPAQ, men significantly reported higher walking time (99.31±95.22 METS vs. 33.28±37.42 METS, p=0.001, respectively) and higher total physical activity (4164.91±4164.91 METS vs. 1390.68±1609.05 METS, p<0.001, respectively) than women. In relation to technology usage, the entire sample used a mobile phone, whilst there were no significant gender differences in the functions/applications used (phone calls, text messages, camera, receive videos/photos, internet searches, apps, instant messages, social media, games) (p=0.068). Although the majority of the participants (85.71%) had regular access to internet, men used their phone more frequently than women (81.10% vs. 37.50%, p=0.005, respectively). Comparison by gender showed no significant differences in the type of device used for internet searches (computer, tablet, mobile phone) (p=0.169), familiarization with technology-based physical activity games (p=0.801), use of heart rate monitors (p=0.193), preference to monitor heart rate when exercising (p=0.664), nor use of other devices to monitor physical activity (pedometer, etc.) (p=0.193).
Conclusion
Based on the results obtained, we conclude that men with CAD were more physical active and used the Internet more often than women, whilst there were no differences by gender in the rest of variables. Assessment of physical activity and technology usage should be implemented in patients with CAD, in order to adapt and improve the design of technology-based telerehabilitation programs
Collapse
Affiliation(s)
- E Munoz Gomez
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - N Moreno-Segura
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - T Sentandreu-Mano
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - P Deka
- College of Nursing, Michigan State University , East Lansing, Michigan , United States of America
| | - L Klompstra
- Department of Medical and Health Sciences Linkoping University , Linkoping , Sweden
| | - D Pathak
- Michigan State University, Department of Statistics and Probability , East Lansing, Michigan , United States of America
| | - N Sempere-Rubio
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - L Orihuela
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - J Mont
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - M Cruz
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| | - M Westas
- Department of Medical and Health Sciences Linkoping University , Linkoping , Sweden
| | - E Marques-Sule
- University of Valencia, Department of Physiotherapy , Valencia , Spain
| |
Collapse
|
9
|
Kohls Ilgner G, Cerrillo M, Pacheco A, Cruz M, Toribio M, García-Velasco J. P-374 Serum progesterone levels on the of embryo transfer in replacement cycles (HRT-ET): soft capsules vs suppositories may make a difference. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Are there differences in serum progesterone levels when vaginal progesterone is administered in soft capsules vs suppositories in HRT-ET?
Summary answer
Mean serum levels of progesterone in embryo replacement cycles are higher when progesterone suppositories are used instead of soft capsules.
What is known already
Serum levels of progesterone on the day of the embryo transfer has captured recent attention, as it may vary among patients and different vaginal progesterone formulations. Previous studies have suggested that natural micronized vaginal progesterone induces a comparable decidual transformation and clinical pregnancy rates to vaginal progesterone gel. However, no data exists comparing suppositories versus soft capsules.
Study design, size, duration
Prospective, observational, single center study to compare serum progesterone levels on the day of the embryo transfer in women undergoing HRT-ET and being treated with vaginal progesterone in capsules or suppositories. Also, a patient satisfaction questionnaire was given to women participating in the study to investigate patient experience. Sample size calculation estimated 50 patients per group needed for a = 0.05 and power 90%, considering standard deviation of 5.1.
Participants/materials, setting, methods
From April to October 2021, 100 patients undergoing HRT-ET were recruited. Only one type of progesterone was administered. 50 patients received soft capsules (Progeffik©, Utrogestan©) and the other half suppositories (Cyclogest©). After estradiol priming for 10-12 days and once confirmed that endometrial thickness was >7mm, 400 mg vaginal progesterone was started b.i.d. Blood was drawn on the day of embryo transfer by venipuncture and progesterone levels in blood were evaluated.
Main results and the role of chance
Mean serum levels of progesterone were significantly higher when suppositories were compared with soft capsules (16.2 ± 7 vs 12.5 ± 5.2 ng/ml, p = 0.0034). According to our previous studies we considered an adequate cut-off of progesterone of 8.8 ng/ml, and patients with a suboptimal serum level of progesterone were supplemented with subcutaneous progesterone. Of those patients receiving suppositories, only 6 out 50 (12%) required subcutaneous supplementation, whereas it was needed in 12 out of 50 (24%) women receiving soft capsules. No differences were observed in pregnancy rate (70% vs 50%) or ongoing pregnancy rate (48% vs 36%).
Regarding patient satisfaction, no differences were observed in the frequency of itching, burning, leakage of medication or drowsiness between groups.
Limitations, reasons for caution
We should consider the limited sample size and the study design, not randomized, before generalizing the results observed.
Wider implications of the findings
In luteal support of frozen embryo replacement cycles, vaginal progesterone suppositories yields superior progesterone serum levels than soft capsules.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- G Kohls Ilgner
- Gynaecologist, Reproductive Medicine , Madrid Spain, Argentina
| | - M Cerrillo
- IVIRMA Madrid, Reproductive Medicine , Aravaca, Spain
| | - A Pacheco
- IVIRMA Madrid, Director Andrology Lab , Madrid, Spain
| | - M Cruz
- IVIRMA Madrid, MedAFF , Madrid, Spain
| | - M Toribio
- IVIRMA Madrid, Nurse. Investigation , Madrid, Spain
| | - J.A García-Velasco
- IVIRMA Madrid, Medical Director , Madrid, Spain
- IIS la Fe, IVI Foundation , Valencia, Spain
- URJC, Medicine , Alcorcon, Spain
| |
Collapse
|
10
|
Bravo VV, Cruz M, González C, Ruíz M, Requena A. P-624 The type of vaccine received against SARS-CoV-2 does not affect ovarian function in an Assisted Reproduction cycle. Hum Reprod 2022. [PMCID: PMC9384343 DOI: 10.1093/humrep/deac105.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Study question Do the different types of vaccines against SARS-CoV-2 influence the results of an Assisted Reproduction treatment? Summary answer The type of vaccine administered against SARS-CoV-2 does not affect the results in women performing an Assisted Reproduction treatment. What is known already Since the COVID-19 pandemic was declared, the search for vaccines has become the priority, so its development has represented a step towards herd immunity in a short period of time. Despite this encouraging advance, vaccine hesitancy in reproductive-aged women has been heightened because of the spread of misinformation stating that COVID-19 vaccines will cause sterility. Due to the lack of information and the clinical relevance, the objective of this work was to evaluate the impact of the different types of vaccines on women’s fertility. Study design, size, duration Retrospective and observational study during January-October 2021 in women vaccinated against SARS-CoV-2 and performing an Assisted Reproductive treatment in any of the 11 clinics belonging to the IVIRMA group in Spain. The Control group included patients performing a treatment during the same study period but who had not yet been vaccinated. The study was approved by an Institutional Review Board (2109-MADR-084-AR) Participants/materials, setting, methods All women, those who had received the complete vaccination schedule, regardless of the type of vaccine administered mRNA or viral vector, and women from the control group underwent the same ovarian stimulation protocol. The Assisted Reproduction treatment was performed with their own oocytes in all cases. Statistical analyses were performed using the Statistical Package for Social Sciences 19.0 (IBM Corporation, Armonk, NY, USA). Main results and the role of chance We included 510 patients distributed as follows: 13.5% (n = 69) received a viral vector vaccine either the adenovirus serotype 26 vector vaccine (Ad26.CoV2.S; Johnson & Johnson; n = 31) or the chimpanzee adenovirus vector vaccine (ChAdOx; AstraZeneca; n = 38). The remaining 86.5% (n = 441) received an mRNA vaccine from either Pfizer-BioNTech (n = 336) or Moderna (n = 105). Sample size for control group was n = 1190 Our results showed that women vaccinated with Johnson & Johnson have a higher average age (39.7 ± 4.3) than the other groups, although no statistical difference was observed (p = 0.072); that is, AstraZeneca (36.8 ± 1.7), Moderna (35.7 ± 1.5), Pfizer (34.6 ± 1.6) and the control group (37.8 ± 2.7). This circumstance did not affect other parameters such as the days of stimulation (p = 0.336) or the doses of FSH administered (p = 0.392), where no statistical differences were recorded between the vaccinated and the control group. Finally, the number of oocytes were as follows, Johnson & Johnson (9.2 ± 2.6), AstraZeneca (7.7 ± 1.2), Moderna (11.3 ± 1.8), Pfizer (12.6 ± 1.0), and the control group (10.2 ± 1.5), p = 0.06. Limitations, reasons for caution This is an observational study, and thus possible confounders cannot be excluded entirely. More data are needed to draw firm conclusions, and it will be critical to increase the sample size to check if the results observed in this work remains in the general population Wider implications of the findings This is the first study to assess whether the type of vaccine administered against SARS-CoV-2, mRNA, or viral vector, affects ovarian function in ART. These early findings suggest no measurable detrimental on ovarian response regardless of vaccine received. Trial registration number not applicable
Collapse
Affiliation(s)
- V. Vergara Bravo
- IVI Madrid, IVI RMA Global Headquarters Medical Affairs , Madrid, Spain
| | - M Cruz
- IVI Madrid, IVI RMA Global Headquarters Medical Affairs , Madrid, Spain
| | - C González
- IVI Sevilla, IVI RMA Headquarters Medical Affairs , Sevilla, Spain
| | - M.E Ruíz
- IVI Madrid, IVI RMA Global Headquarters Medical Affairs , Madrid, Spain
| | - A Requena
- IVI Madrid, IVI RMA Global Headquarters Medical Affairs , Madrid, Spain
| |
Collapse
|
11
|
Herraiz S, Ruiz P, Garrido N, Ballester A, Vergara V, Cruz M, Requena A, García-Velasco JA, Muñoz M. P-796 Intraovarian injection of plasma rich in growth factors improves ovarian reserve and reproductive outcomes in women with diminished ovarian reserve. Hum Reprod 2022. [DOI: 10.1093/humrep/deac104.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Does Plasma rich in growth factors (PRGF) ovarian injection increase the ovarian reserve biomarkers in women with diminished ovarian reserve?
Summary answer
PRGF injection increased Antimüllerian hormone (AMH) levels and antral follicular count (AFC) since the first follow-up after treatment allowing the initiation of ovarian stimulation cycles.
What is known already
Several techniques based on in vitro activation, ovarian fragmentation and stem cell ovarian transplantation have been proposed to reactivate ovarian function and increase IVF success in women with premature ovarian insufficiency and poor ovarian response. However, less invasive and feasible approaches are still required for those patients where egg donation is the only practical option.
Platelet rich plasma (PRP) and PRGF contain a high concentration of platelets, which carry more than 800 types of proteins, cytokines, hormones, and chemoattractants. Indeed, intraovarian PRP injection has recently been used in different case series and cohort studies of POI women with encouraging results.
Study design, size, duration
Retrospective study with 104 women aging 23-45 years who received a PRGF intraovarian injection (REGENERA-Ovario) was conducted between 2020 and 2021 at IVIRMA Alicante (Spain). Study was approved by the IRB committee of La Fe University Hospital (2112-FIVI-109-SH).
Participants/materials, setting, methods
Patients underwent a PRGF injection (Endoret kit; B.T.I. Biotechnology Institute S.L, Spain) in both ovaries and a follow up of ovarian reserve biomarkers (AFC, AMH) and follicle stimulating hormone (FSH) to evaluate follicular reactivation seeking IVF or spontaneous pregnancy. The follow up visits ranged from 1 to 5 months and were developed on a monthly basis after treatment or after menses recovery in POI. Study variables were compared to basal levels with a paired t-test.
Main results and the role of chance
Overall, 104 women (age: 38.7±2.0 years; BMI: 22.1±2.9) with diminished ovarian reserves underwent a PRGF intraovarian injection (3.3±0.8ml PRGF/each ovary). Prior to treatment, our cohort was characterized high serum FSH (21.8±4.1mIU/mL), low AMH levels (0.25±0.37ng/ml), and an ovarian volume of 6.3±2.3cm3.
Eighty-eight of them fulfilled the 1st follow up visit and showed an increase of serum AMH (0.25±0.37ng/ml vs. 0.32±0.36ng/ml, p = 0.008), and AFC in both ovaries (2.1±1.9 vs. 3.2±2.4, p < 0.0001) compared to basal levels, achieving ovarian reactivation in 55.9% of them and IVF cycle initiation in 19.3%. These improvements were higher 2 months after treatment (55 patients), with increased antral follicles (AFC-2: 2.9±2.5, p = 0.0001) and ovarian activation in 58.2%, and IVF start in 43.9% of patients. Similar results were observed during the 3rd follow up accomplished by 30 women and lasted until the 5th visit (n = 8), although the reduced patient number at this point.
A total of 44 IVF cycles were started and oocyte pick-up was successfully developed in 72.7% of them with a mean number of 3.3±4.2MII oocytes, 1.8±2.1 fertilized oocytes and 1.5±2.0 embryos per cycle. Indeed, 6 pregnancies were obtained during this period, 2 of them after embryo transfer and 4 by natural conception.
Limitations, reasons for caution
Our results are encouraging but a large cohort of patients with a longer follow up period is needed to establish the efficacy and duration of the PRGF positive ovarian effects. Moreover, a proper comparison with a control group with the same characteristics and no PRGF intervention is still required.
Wider implications of the findings
PRGF intraovarian injection reactivates follicle growth and allows IVF cycle initiation and embryo generation in a poor prognosis population of patients with diminished ovarian reserve. The effects persisted for several months after treatment.
Trial registration number
2112-FIVI-109-SH
Collapse
Affiliation(s)
- S Herraiz
- Fundación IVI-IIS La Fe, Innovation , Valencia, Spain
| | - P Ruiz
- IVIRMA Alicante, Reproductive Medicine Unit , Alicante, Spain
| | - N Garrido
- Fundación IVI-IIS La Fe, Innovation , Valencia, Spain
| | - A Ballester
- IVIRMA Alicante, Reproductive Medicine Unit , Alicante, Spain
| | - V Vergara
- IVIRMA Madrid, Reproductive Medicine Unit , Madrid, Spain
| | - M Cruz
- IVIRMA Madrid, Medical Affairs , Madrid, Spain
| | - A Requena
- IVIRMA Madrid, Medical Affairs , Madrid, Spain
| | | | - M Muñoz
- IVIRMA Alicante, Reproductive Medicine Unit , Alicante, Spain
| |
Collapse
|
12
|
Giles J, Cruz M, Cobo A, Vidal C, Alama P, Requena A, Bosch E. P-601 Is Medroxiprogesterone acetate (MPA) an adequate alternative to GnRH antagonist in oocyte vitrification for non oncological fertility preservation (FP) and preimplantation genetic test (PGT-A) cycles? Hum Reprod 2022. [DOI: 10.1093/humrep/deac105.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Can we use MPA as a pituitary inhibitor instead of the GnRH antagonist in ovarian stimulation protocols in non-oncological fertility preservation and PGT-A cycles?
Summary answer
MPA can act as a substitute of GnRH antagonist for pituitary suppression in FP and PGT-A cycles, since the results are similar between both groups.
What is known already
Progestin-primed ovarian stimulation (PPOS) protocols using exogenous progesterone to replace GnRH analogs during the follicular phase of OS have emerged as an efficient alternative to prevent LH from peaking and have been used successfully in different types of patients.
Fertility preservation (FP) and preimplantation genetic testing (PGT-A) have become new emerging areas of assisted reproduction. FP gives women the ability to have children using their own gametes after age-related fertility decline, while PGT-A appears to improve reproductive outcomes in advanced maternal age at increased risk of aneuploid embryos. However, few data are available for both indications regarding PPOS cycle outcomes.
Study design, size, duration
Multicenter, retrospective, observational, cohort study conducted in eleven IVIRMA centers attached to private universities.
We included a total of 4,961 cycles of non-oncological fertility preservation that were distributed as follows: n = 494 were stimulated under a PPOS protocol while n = 4,467 received a GnRH antagonist. Regarding PGT-A cycles, we analyzed 12,461 treatments, of which n = 686 and n = 11,775 received MPA and GnRH antagonist, respectively. Cycles were performed from January 2017 to December 2021.
Participants/materials, setting, methods
Patients were divided according to the protocol used for preventing premature luteinization during follicular phase of OS. In the MPA group, participants received 10 mg daily administered orally, while in the control group, women received an antagonist once the main follicle reached 13 mm.
In FP cycles, ovarian response specific parameters were evaluated, such as endocrine profile and mature oocytes; in PGT-A treatments, main variables were number of biopsied and aneuploid embryos and reproductive outcomes.
Main results and the role of chance
Regarding FP's baseline characteristics, age was statistically but not clinically significant between the two groups. Length of ovarian stimulation and total dose of hMG administered were similar in both groups, despite the significantly higher total dose of FSH administered in MPA compared to the GnRH antagonist group (p = 0.008) . Number of mature oocytes retrieved (10.2 [95% CI 9.6-10.8] vs 9 [95% CI 8.8-9.2]) was significantly higher in MPA compared to antagonist group; this trend continued regardless of age (≤ 35 or > 35 years).
PGT-A cycles followed the same tendency in terms of demographic characteristics. Length of OS was comparable between groups, whilst the total dose of rFSH and hp-HMG administered in the MPA were significantly higher than that in the GnRH antagonist group. Although the number of MII was comparable and despite the lower number of embryos biopsied in the MPA group (4.5±0.2 vs 4.7±0.06, p = 0.031) the number of aneuploid embryos was similar between the two groups (2.3±0.1 vs 2.4±0.04, p = 0.474), as well as implantation (56% vs. 54% p = 0.359) and clinical pregnancy rate (64.1% vs. 62.1, p = 0.316). The miscarriage rate was significantly lower in the group treated with MPA compared to GnRH antagonists (4.7% vs. 8.2%, p = 0.001).
Limitations, reasons for caution
The retrospective nature of this study may be a reason for caution and only association, not causation, can be inferred from the results. Despite being the largest sample size ever reported with PPOS in no oncological FP and PGT-A, the number of patients included is still low.
Wider implications of the findings
The administration of PPOS yielded similar or even better results than those observed with GnRH antagonists in terms of oocytes retrieved, rate of aneuploid embryos or clinical results. Therefore, PPOS could be recommended for ovarian stimulation in non-oncological FP and PGT-A cycles as it allows for a more patient-friendly approach.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- J Giles
- IVIRMA Valencia, Reproductive Medicine , Valencia, Spain
| | - M Cruz
- IVIRMA Madrid, Reproductive Medicine , Madrid, Spain
| | - A Cobo
- IVIRMA Valencia, Cryopreservation , Valencia, Spain
| | - C Vidal
- IVIRMA Valencia, Reproductive Medicine , Valencia, Spain
| | - P Alama
- IVIRMA Valencia, Reproductive Medicine , Valencia, Spain
| | - A Requena
- IVIRMA Madrid, Reproductive Medicine , Madrid, Spain
| | - E Bosch
- IVIRMA Valencia, Reproductive Medicine , Valencia, Spain
| |
Collapse
|
13
|
Trinchant R, Cruz M, Mugica A, Colomé C, Requena A. P-715 (In)fertility perceptions in a cohort of 1569 women. Hum Reprod 2022. [DOI: 10.1093/humrep/deac105.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Which are the perceptions and knowledge regarding female fertility and infertility of Spanish women?
Summary answer
Infertility carries a social stigma that prevents women from sufficient knowledge or professional aid to take their reproductive choices adequately.
What is known already
Infertility is a pathology that remains on an invisible plane for society. It is estimated that up to a third of all IVF cycles performed due to low ovarian reserve would be avoidable if women had received sufficient information at the right time. The factors that mainly contribute to this phenomenon are the marked social stigma that it entails, the lack of knowledge regarding tools, possibilities and real expectations in fertility and the low socio-sanitary involvement regarding tasks and campaigns to increase social awareness in this specific field.
Study design, size, duration
This is a cross-sectional study carried out using a population-based survey to identify different attitudes, knowledge and opinions regarding fertility and infertility. The survey was made public on April 30, 2019 and closed on May 10, 2019.
Participants/materials, setting, methods
A total of 1569 Spanish women answered all the questions included in the survey. No response or subject participation was excluded from the study. The platform used to create the questionnaire was Google Forms, which anonymizes the responses automatically. Data processing was performed using RStudio, an integrated development for R scripting.
Main results and the role of chance
Up to 1231 women had not had children at the time of the survey and 46% (566) of these cohort were either worried or very concerned about not being able to conceive naturally in the future. Also, 71% (871) of the same cohort were willing to have children of their own. In addition, 65% (1015) among those surveyed though that infertility had an important social stigma. With respect to gynecological health, 89% (1376) of women surveyed had had at least a gynecologic check-up at the time of answering the survey. However, up to 78% (921) of this cohort had never consulted their gynecologist regarding female fertility. Women surveyed were asked to predict the age at which conceiving a child both naturally and via assisted reproductive techniques started to become difficult. Respondents predicted that age to be 36.74 (IC95% [36.52, 36.96]) years and 39.79 (IC95% [39.58, 40.01]) years, respectively. Plus, 86% (1328) of women surveyed were in favor of elective fertility preservation and up to 72% (1127) thought that the Spanish State should either cover or aid economically this process. Finally, up to 72% (1115) of them thought they lacked important information to take their reproductive choices adequately.
Limitations, reasons for caution
Participants in the survey were exclusively contacted virtually. Even with the number of responses obtained and due to the descriptive nature of this study, it might not be representative of Spanish female society regarding the topics addressed. Also, the results here presented might not be extrapolable to other populations.
Wider implications of the findings
Considering the data presented in this work, education in fertility should start as soon as possible, ideally in high school. Finally, reproductive autonomy is being able to choose whether to have or not to have children, but the key is to always be able to make that decision.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- R Trinchant
- IVI RMA Mallorca, IVF Laboratory , Palma, Spain
| | - M Cruz
- IVI RMA Madrid, IVIRMA Headquarters , Madrid, Spain
| | - A Mugica
- IVI RMA Mallorca, IVF Laboratory , Palma, Spain
| | - C Colomé
- IVI RMA Mallorca, Reproductive Medicine , Palma, Spain
| | - A Requena
- IVI RMA Madrid, IVIRMA Headquarters , Madrid, Spain
- IVI RMA Madrid, Medical Affairs , Madrid, Spain
| |
Collapse
|
14
|
Peixoto C, Rego D, Cruz M, Medeiros H. “Dad is feeling blue”: what to know about paternal perinatal depression. Eur Psychiatry 2022. [PMCID: PMC9566303 DOI: 10.1192/j.eurpsy.2022.1224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Introduction The transition into parenthood is associated with an increased psychopathological vulnerability. Most studies have focused on mothers, although recently, the role of fathers has grown more importance. Paternal perinatal depression (PPD) is an episode of major depressive disorder occurring in new or expectant fathers during the perinatal period. PPD is not widely acknowledged and research are rare. Objectives The authors intend to review the literature about PPD, focusing on its prevalence, risk factors, clinical features, treatment and consequences. Methods Non-systematic review of the literature through PubMed. Results A meta-analysis of PPD estimated a prevalence of 10.4%. Risk factors of PPD are multiple and complex. There are sociodemographic factors, such as marital status, monthly income and social support. Psychological factors, for instance history of depression, maternal prenatal anxiety and maternal depression. Some literature also suggests hormonal changes on men like increase estrogen and lower testosterone levels. PPD can present with symptoms of mood alterations, like irritability and restricted emotions, anxiety, fatigue, insomnia, loss of appetite. Also common are behavioural disturbances such as interpersonal conflicts, impulsivity, violence, avoidance behaviour, and substance abuse. There are no studies to specific treatments to PPD, so the treatment is the same for women, such as antidepressants and psychotherapy. If untreated, PPD can have an adverse influence on the health and wellbeing of the mother and child. Conclusions PPD is still underscreened, underdiagnosed and undertreated. It is fundamental identifying risk factors and the development of specific interventions. Further research on PPD is needed. Disclosure No significant relationships.
Collapse
|
15
|
Peixoto C, Rego D, Cruz M, Peixoto B, Bicho M, Coelho J, Medeiros H. Challenges of ageing in prisons and forensic psychiatric settings. Eur Psychiatry 2022. [PMCID: PMC9567742 DOI: 10.1192/j.eurpsy.2022.1554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction There is a current trend towards an increase in the number of elderly prisoners due to the increase in life expectancy and the change in the attitude of society and the judicial system. The cut-off for “older offender” is defined from the age of 50, due to the lifestyle previous to prision and premature ageing. Objectives The authors intend to understand the challenges of aging in prison and forensic services, highlighting the psychiatric comorbidities of inmates and how these services can adapt to the needs of this population. Methods Non-systematic review of the literature. Results Studies of elderly in prisons and elderly forensic psychiatric patients are limited. Prisoners have increased physical and psychiatric morbidity and early mortality as they are more exposed to risk factors and more likely to have at least one health problem compared to older adults in the community. Compared to older people in the community, older prisoners are at higher risk for most psychiatric disorders including depression, psychosis, bipolar disorder, cognitive impairment, personality disorder and anxiety. Suicide rates are also higher among elderly prisoners. The inadequacy of the prison system to respond to the unique needs of elderly prisoners has a detrimental impact on their overall experience of incarceration. The development of specific services for elderly prisoners or the adaptation of mixed units for the elderly population is proposed. Conclusions The elderly population in prisons is growing and has higher risk of psychiatric pathology compared to community elders. Prison services with difficulties in identifying and meeting these needs. Disclosure No significant relationships.
Collapse
|
16
|
Bergevin A, Husain M, Cruz M, Blanc CL, Dieme A, Girardin ML, Toujouse C, Tkhayat RB, Slabab S, Corseri O, Maglorius M, Vercamer C, Eskander E, Desselas E, Lachaume N, Garraffo A, Sorge F, Roux EL, Gaschignard J, Caseris M, Faye A. Medical check-up of newly arrived unaccompanied minors: A dedicated pediatric consultation service in a hospital. Arch Pediatr 2021; 28:689-695. [PMID: 34756657 DOI: 10.1016/j.arcped.2021.09.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 03/15/2021] [Accepted: 09/26/2021] [Indexed: 11/18/2022]
Abstract
BACKGROUND AND AIMS Healthcare for the increasing number of migrants in Europe, and particularly of unaccompanied minors (UMs) seeking asylum, has become a major challenge. We aimed to describe the health issues of UMs managed in a dedicated pediatric consultation service in a care center in Paris. METHODS All UMs attending a dedicated migrant medical consultation service in Robert Debré Hospital, Paris, France, were included in a single-center retrospective observational study from September 1, 2017, to September 30, 2018. RESULTS Out of the 107 UMs who were included, 87% had a health problem (n=93) and 52% had an infectious disease (n=56). The main infectious diagnoses were schistosomiasis (22%), latent tuberculosis (22%), intestinal parasitosis (16%), and chronic hepatitis B (8%). Posttraumatic stress disorder (PTSD) and overweight were common (35% and 20%, respectively). The median age was 15 years old (IQR, 14-16), the male/female ratio was 95/12. Most of the children were from sub-Saharan Africa (n=67), 46% had crossed Libya (n=49) and, when compared to the other migration routes, faced an increasing risk of violence (69%, p=0.04), imprisonment (53%, p=0.03), and forced labor (48%, p=0.02). The median duration of the trip before reaching France was 6 months (IQR, 2-13), the median time to consultation was 2 months (0-5) and was not associated with an increased risk of health problems. A total of 43 UMs were lost to follow-up. CONCLUSION Health problems, particularly infectious diseases and PTSD, are common among UMs and should prompt an early medical consultation with psychiatric evaluation. Follow-up is problematic and could be improved by an on-line health book.
Collapse
Affiliation(s)
- A Bergevin
- General Pediatric Department, Nord Ouest Hospital, Villefranche sur Saône, 69655 France; Pediatric Residents Association, AJP, Paris, 75 France.
| | - M Husain
- Pediatric Residents Association, AJP, Paris, 75 France
| | - M Cruz
- Pediatric Residents Association, AJP, Paris, 75 France; APHP, General Pediatric Department Robert Debré Hospital, Paris 75019 France
| | - C Le Blanc
- Pediatric Residents Association, AJP, Paris, 75 France; APHP, General Pediatric Department Jean Verdier Hospital, Bondy 93140 France
| | - A Dieme
- Pediatric Residents Association, AJP, Paris, 75 France; General Pediatric Department Ambroise Paré, Boulogne-Billancourt 92100 France
| | - M-L Girardin
- Pediatric Residents Association, AJP, Paris, 75 France; Pediatric Intensive Care Unit, Hautepierre Hospital, Strasbourg 67200 France
| | - C Toujouse
- Pediatric Residents Association, AJP, Paris, 75 France
| | - R Ben Tkhayat
- Pediatric Residents Association, AJP, Paris, 75 France
| | - S Slabab
- Pediatric Residents Association, AJP, Paris, 75 France
| | - O Corseri
- Pediatric Residents Association, AJP, Paris, 75 France; APHP, General Pediatric Department Robert Debré Hospital, Paris 75019 France
| | - M Maglorius
- Pediatric Residents Association, AJP, Paris, 75 France
| | - C Vercamer
- Pediatric Residents Association, AJP, Paris, 75 France; APHP, General Pediatric Department Jean Verdier Hospital, Bondy 93140 France
| | - E Eskander
- Pediatric Residents Association, AJP, Paris, 75 France
| | - E Desselas
- Pediatric Residents Association, AJP, Paris, 75 France; General Pediatric Department Montpellier Hospital, Paris 34295 France
| | - N Lachaume
- APHP, General Pediatric Department Robert Debré Hospital, Paris 75019 France; APHP, General Pediatric Department Louis Mourier Hospital, Colombes, 92700 France
| | - A Garraffo
- APHP, General Pediatric Department Robert Debré Hospital, Paris 75019 France; Pediatric Department, Villeneuve-Saint-Georges Hospital, Villeneuve-Saint-Georges, 94190 France
| | - F Sorge
- APHP, General Pediatric Department Robert Debré Hospital, Paris 75019 France; APHP, General Pediatric Department Necker Hospital, Paris, 75015 France
| | - E Le Roux
- Clinical Epidemiology Department Robert Debré Hospital, Paris, 48 boulevard Sérurier 75019 France; Paris Diderot Medical University, 10 avenue de Verdun Paris, 75010 France; ECEVE, INSERM 1123, 10 avenue de Verdun Paris, 75010 France
| | - J Gaschignard
- APHP, General Pediatric Department Robert Debré Hospital, Paris 75019 France
| | - M Caseris
- APHP, General Pediatric Department Robert Debré Hospital, Paris 75019 France
| | - A Faye
- APHP, General Pediatric Department Robert Debré Hospital, Paris 75019 France; Clinical Epidemiology Department Robert Debré Hospital, Paris, 48 boulevard Sérurier 75019 France; Paris Diderot Medical University, 10 avenue de Verdun Paris, 75010 France.
| |
Collapse
|
17
|
Cerrillo Martínez M, Cecchino GN, Cruz M, Toribio M, García Rubio MJ, García Velasco JA. O-111 The DuoStim strategy shortens the time to obtain an euploid embryo in poor prognosis patients: a non-inferiority, randomized controlled trial. Hum Reprod 2021. [DOI: 10.1093/humrep/deab126.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Is there any difference in the time to obtain euploid embryos from poor prognosis patients who performed two conventional cycles versus double stimulation (DuoStim) in the same cycle?
Summary answer
DuoStim showed similar ovarian response and in vitro fertilization (IVF) laboratory outcomes while shortening the time to obtain an euploid embryo in poor prognosis patients.
What is known already
Several waves of cyclic development of antral follicles within the same menstrual cycle have been demonstrated. Likewise, it has been shown that oocytes obtained from luteal phase ovarian stimulation (OS) have similar competence than those obtained in the follicular phase OS. Often, some patients require sequential OS in order to obtain more oocytes and increase their chances to reach embryo transfer. Thus, the DuoStim strategy could be an attractive alternative to reduce the time-to-pregnancy. However, prospective data and randomized trials that validate this strategy are lacking.
Study design, size, duration
We conducted a prospective, randomized controlled trial at our institution from[MCM1] [JAGV2] January 2017 to December 2020. A total of 80 poor prognosis patients aged over 38 years undergoing PGT-A were enrolled in two groups: 39 patients did two OS in consecutive cycles (control) whereas 41 women underwent two OS in the same menstrual cycle (DuoStim).
Participants/materials, setting, methods
Poor prognosis was defined as suboptimal responders. The primary outcome was the time needed to obtain an euploid embryo. The secondary outcomes were duration of stimulation, dose of gonadotropins, oocyte maturity rate, fertilization and blastocyst formation rates. Variables were expressed as mean ± standard deviation. Statistical analyses was performed by ANOVA and Chi-square tests, as appropriate. Differences were considered significant when p-value < 0.05.
Main results and the role of chance
The patients’ baseline characteristics were similar between groups. We did not find any difference in the mean days of stimulation between the control and the DuoStim group (21.3 ± 1.6 vs. 23 ± 1.4, p = 0.105), nor in the amount of gonadotropin required (4005 ± 450 vs. 4245 ± 430, p = 0.43), number of MII oocyte (8.7 ± 1.8 vs. 6.8 ± 1.7, p = 0.159), blastocyst rate (51.4% vs. 34.8%, p = 0.113) and the number of euploid embryos (0.8 ± 0.4 vs. 0.6 ± 0.4, p = 0.45). However, there was a significant difference in the average number of days until reaching an euploid blastocyst, favoring the DuoStim group (44.1 ± 2 vs. 23.3 ± 2.8, p < 0.001). Comparing the follicular versus the luteal phase within the DuoStim group, the only difference detected concerns to the mean days of stimulation (10.3 ± 0.8 vs. 12.7 ± 0.9, p < 0.001). We also observed a trend towards a higher fertilization (38.1% vs. 61.8%, p = 0.02) and blastulation rate (23% vs. 53%, p = 0.03) in the luteal phase of the DuoStim cycle.
Limitations, reasons for caution
The major limitation is related to the limited sample size, as it limits our power analysis (70%). On the other hand, it is one of the first randomized prospective pilot trial that compared the efficiency of performing two consecutive ovarian stimulation in different menstrual cycles with the DuoStim strategy.
Wider implications of the findings
This study clearly showed that the DuoStim protocol is not inferior to the conventional stimulation in terms of ovarian response and laboratory outcomes. Moreover, the DuoStim reduces the time to obtain an euploid embryo in poor prognosis patients, which is of great clinical utility.
Trial registration number
NCT03291821
Collapse
Affiliation(s)
| | - G. N Cecchino
- Department of Reproductive Medicine- Mater Prime São Paulo- Brazil, Reproductive Medicine, Säo paulo, Brazil
| | - M Cruz
- IVIRMA Madrid, Equipo IVI, Madrid, Spain
| | - M Toribio
- IVIRMA Madrid, Nurse and investigation department, madrid, Spain
| | | | | |
Collapse
|
18
|
Nogale. Barrios MDC, García-Velasco JA, Cruz M, Frutos SD, Martínez EM, Gaytán M, Ariza M, Bronet F. P–415 Clinical and In Vitro Fertilization laboratory parameters that contribute to clinical miscarriage after single euploid embryo transfer. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
To investigate which factors, excluding embryo aneuploidies, are associated with miscarriage in patients who have undergone a single euploid blastocyst transfer.
Summary answer
Miscarriage was related to the body mass index (BMI), the type of cycle and the thickness of the endometrium.
What is known already
Preimplantation genetic testing for aneuploidies (PGT-A) is widely used in-vitro fertilization (IVF) to select euploid embryos. Several studies have shown that embryo aneuploidy is the main contributing factor for IVF failure, reinforcing the relevance of PGT-A as a method to select chromosomally normal embryos.
A recent meta-analysis confirmed that patients undergoing PGT-A have a lower miscarriage rate than women that conceived naturally (9% vs 28%, respectively).
Even though most of the studies show that PGT-A significantly reduces miscarriage rate, still some women do lose their pregnancies. We investigated which other reasons may be related to this early pregnancy loss.
Study design, size, duration
Retrospective, observational, and multicenter study of 6910 patients undergoing single euploid blastocyst transfer after PGT-A from January 2017 to December 2019 in our institution. Several laboratory and clinic variables were analyzed to study the effect of these variables on the miscarriage rate
Participants/materials, setting, methods
Indications for PGT-A were advanced maternal age, implantation failure, recurrent pregnancy loss and male factor. Embryos were cultured 5% O2 concentration and 6.5% CO2 concentration. Trophectoderm biopsy was performed on day 5/6 of development and analyzed through Next Generation Sequencing (NGS); embryos were vitrified until transfer was performed. Single euploid embryo transfer was performed in all cases.
We performed a multivariate regression analysis to compare the different variables and search for there are significant differences.
Main results and the role of chance
We studied a total of 6910 patients undergoing PGT-A to describe which factors, excluding embryo aneuploidies, were correlated with miscarriage in patients who underwent single thawed euploid embryo transfer.
When considering embryo morphology (embryo grading, quality of inner cell and quality of trophectoderm), we did not find differences in miscarriage rate among groups (high quality= 15.9%; normal quality= 14.3%; low quality= 15.0%; poor quality= 14.8%) p = 0.833.
BMI was significantly associated with miscarriage rate (odds ratio [OD] 1.04; 95% confidence interval [CI], 1.012–1–076 p = 0.006) and miscarriage rate.
We observed a weak association between endometrial thickness and miscarriage rate ([OD] 0.65; 95%, 0.528–0.778 p = 0.04) and also between type of endometrial preparation (natural cycle or hormone replacement cycle) ([OD] 0.77; 95%, 0.528–0.778) p = 0.04.
Body mass index, according to our findings, was the main variable correlated with miscarriage rate. We did not find any association with the other variables studied (biopsy day, maternal age, male age, duration infertility, cycle length, previous miscarriage, previous live birth, previous cycles IVF, endometrial pattern and diagnosis).
Limitations, reasons for caution
The retrospective study design limits the generalization of our results but offers a good insight to be validated in prospective trials.
Wider implications of the findings: According to our findings, BMI, endometrial thickness the day of the embryo transfer, and the type of endometrial preparation should be considered when transferring an euploid blastocyst.
Trial registration number
NO APLICA
Collapse
Affiliation(s)
| | | | - M Cruz
- IVI Madrid, IVI Madrid, madrid, Spain
| | | | | | - M Gaytán
- IVI Madrid, PGD Team, madrid, Spain
| | - M Ariza
- IVI Madrid, PGD Team, madrid, Spain
| | - F Bronet
- IVI Madrid, PGD and IVF Laboratory, madrid, Spain
| |
Collapse
|
19
|
Trinchant R, Cruz M, Requena A. P–287 Uterine adenomyosis does not affect perinatal outcomes in ART treatments. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Is adenomyosis associated with worse clinical and perinatal outcomes in ovum donation cycles?
Summary answer
Adenomyosis was associated with reduced live birth rate per embryo transfer but not with increased risk of miscarriage or worse perinatal outcomes than controls.
What is known already
The effect of adenomyosis on IVF/ICSI outcomes are controversial as studies addressing this issue are limited in number and heterogeneous. Conclusions withdrawn from previous works differ regarding the prospective or retrospective design of the study. Two different metanalysis conducted showed that adenomyosis reduced implantation and clinical pregnancy rate and increased miscarriage risk. However, current data regarding perinatal outcomes of assisted reproduction techniques cycles in patients diagnosed with uterine adenomyosis is scarce.
Study design, size, duration
A retrospective cohort study in which 3307 patients undergoing ovum donation cycles were included. Patients who underwent single embryo transfer (SET) between years 2018 and 2019 were included and divided into two groups: adenomyosis (n = 179) and controls (n = 3218).
Participants/materials, setting, methods
Inclusion criteria consisted of patients in an oocyte donation program who had fresh SET on day 5 blastocyst stage development. Patients diagnosed with miomas and/or severe endometriosis and those who had undergone previous uterine surgical interventions were excluded from the study. Cases consisted of patients with a history of either focal or diffuse adenomyosis diagnosed via transvaginal ultrasonography (TVUS).
Main results and the role of chance
Clinical pregnancy rate per embryo transfer was 82/179 (45.8%) in those women diagnosed with adenomyosis versus 1869/3218 (59.8%) in control group (OR = 0.57 95% CI. 0.41–0.78, p < 0.001). Miscarriage rate was similar in the two study groups and differences found were not statistically significant, being 15/82 (18.3%) for adenomyosis and 309/1869 (16.5%) for control group. A lower live birth rate per embryo transfer was observed in women diagnosed with adenomyosis versus control, being 68/179 (38%) and 1560/3128 (49.9%) respectively (OR = 0.615 95% CI 0.44–0.85, p = 0.002). There were no statistically significant differences between childbirth delivery methods (vaginal versus caesarean section). Furthermore, means of gestational age at the time of delivery, newborn size and weight and incidences of low birth weight, preterm birth and admission in neonate intensive care unit (NICU) did not differ between the two groups. In addition, IVF and perinatal outcomes were similar in patients with diffuse adenomyosis compared to focal adenomyosis.
Limitations, reasons for caution
This is an observational study and thus possible confounders cannot be completely excluded. Diagnostic of adenomyosis is complex and, despite imaging via TVUS is both sensitive and specific, different criteria may be combined in order to fully assess the diagnostic.
Wider implications of the findings: Published literature has described how adenomyosis negatively impacts clinical outcomes in ART cycles; however, data regarding perinatal results is scarce. This study is of interest as it provides a first insight for clinicians showing that adenomyosis affects clinical but not perinatal outcomes in ovum donation cycle.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- R Trinchant
- IVI RMA Global, IVF Laboratory, Palma, Spain
| | - M Cruz
- IVI RMA Global, Medical Affairs, Madrid, Spain
| | - A Requena
- IVI RMA Global, Medical Affairs, Madrid, Spain
| |
Collapse
|
20
|
Ortega I, Alamá P, Cruz M, Giles J, García-Velasco JA. P–687 Impact of medroxyprogesterone acetate (MPA) as pituitary suppression on oocyte quality and clinical outcomes in egg donation recipients. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
To compare the impact on oocyte quality and reproductive outcomes in patients who received oocytes from donors stimulated with MPA versus GnRH antagonist protocol.
Summary answer
Compared to GnRH antagonist, MPA does not exert a major effect on oocyte quality and yields similar reproductive outcomes in egg donation recipients.
What is known already
Conventional ovarian stimulation (OS) protocols have classically used GnRH analogues, both agonists and antagonists, to avoid premature follicular luteinization. The oral administration of MPA or micronized progesterone during the follicular phase of OS has emerged as an attractive alternative to conventional protocols in the prevention of early luteinization. Compared to progesterone, MPA is characterized by a moderate-strong progestanic action, lower androgenic properties and does not interfere with the measurement of endogenous progesterone. In our group, administration of MPA during the follicular phase of OS has been included in the routine clinical practice of our donor program since late 2019.
Study design, size, duration
Multicentre, retrospective, observational, cohort study carried out in eleven private university-affiliated IVF centers. The present study included a total of 14,282 fresh ovum donation cycles performed from October 2017 to March 2020. Oocyte donors were recruited and stimulated under either MPA (n = 4,665) or GnRHa (n = 9,617) to suppress the pituitary during the follicular phase of OS, and GnRH agonist was administered to trigger final oocyte maturation in all the participants.
Participants/materials, setting, methods
Recipients were divided according to the protocol used for premature luteinization prevention during the follicular phase of the ovum donation matched-cycle: Group 1, recipients who received oocytes from donors treated with 10 mg/day of MPA (ProgeveraÒ); Group 2, recipients who received oocytes from GnRH antagonist (FyremadelÒ) down-regulated donor cycles. All the procedures were approved by an Institutional Review Board (1910-VLC–091-JG) and complied with Spanish law on assisted reproductive technologies (14/2006).
Main results and the role of chance
Regarding donoŕs baseline characteristics, age and antral follicle count were significantly different between groups, but not clinical differences. The length of ovarian stimulation was similar in both groups (10.7 days [95% Confidence Interval (CI) 10.5–10–8] vs 10.5 days [95% CI 10.0–11.00]). Despite slightly higher mean total dose of FSH administered in Group 1 compared to Group 2 (1.841 IU [95% CI 1.813–1.868] vs 1.739 IU [95% CI 1.723–1.754]), there were no differences in the total dose of hMG administered between both groups (967 IU [95% CI 901–1.034] vs 971 IU [95% CI 944–998]). With regard to IVF data, both the number of retrieved oocytes (22.9 [95% CI 22.4–23.4] vs 24.1 [95% CI 23.8–24.3]), and mature oocytes (18.7 [95% CI 18.3–19.1] vs 19.3 [95% CI 19.1–19.6]), were slightly lower in Group 1 compared to Group 2, whereas fertilization rate was significantly higher in Group 1 compared to Group 2 (82.1% [95% CI 81.7–82.6] vs 80.8% [95% CI 80.6–81.2]),. Regarding the clinical outcomes, no differences were observed in either implantation rate (58.7% [95% CI 56.7–60.7] vs 59.3% [95% CI 57.3–61.3]) or clinical pregnancy rate (59.5% vs 59.8%, P = 0.04) between both groups.
Limitations, reasons for caution
As a consequence of being a retrospective study, only association, and not causation, can be inferred from the results. A further limitation is that donors are healthy young women and do not perfectly match other populations, as infertile patients who may be older, low or high responders to OS.
Wider implications of the findings: MPA emerges as an effective oral alternative to GnRH analogues for preventing premature luteinizing hormone surges in donors undergoing OS in ovum donation program. Compared with GnRH antagonists, MPA has advantages of being an oral administration route and providing easy access, yielding similar clinical results.
Trial registration number
1910-VLC–091-JG
Collapse
Affiliation(s)
- I Ortega
- IVIRMA Madrid, Fertility Department, Madrid, Spain
| | - P Alamá
- IVIRMA Valencia, Fertility Department, Valencia, Spain
| | - M Cruz
- IVIRMA Madrid, Fertility Department, Madrid, Spain
| | - J Giles
- IVIRMA Valencia, Fertility Department, Valencia, Spain
| | | |
Collapse
|
21
|
Cruz M, Requena A. How to provide fertility treatment during COVID-19 pandemic. Curr Opin Obstet Gynecol 2021; 33:159-163. [PMID: 33769422 DOI: 10.1097/gco.0000000000000705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW The emergence of the novel coronavirus infection that arose in Wuhan, China in December 2019 has resulted in an epidemic that has quickly expanded to become one of the most significant public health threats in recent times. The objective of this review is to summarize how this pandemic has affected the activity of a Reproductive Medicine Center, which established a series of measures in parallel with governments decisions and scientific societies. RECENT FINDINGS The control measures adopted for restarting the healthcare activity should be equitable and inclusive. Moreover, this pandemic has implied changes in treatments and strategies to be alert regarding the daily changing information. Finally, for ensuring a safe practice both for patients and staff, it is important to detect asymptomatic patients, so Reproductive Medicine centers must take special care with screening and testing procedures. SUMMARY The pandemic has pushed up toward a new reality in terms of Assisted Reproductive treatments, where social distance and responsibility are protagonists. We face a new challenge of balancing between responding to the committed efforts of infertile couples to achieve pregnancy and safeguarding the health of the future parents and their children during this time of pandemic.
Collapse
Affiliation(s)
- M Cruz
- IVI Madrid, Madrid, Spain
| | | |
Collapse
|
22
|
Cerejeira A, Gomes N, Cruz M, Mota A, Azevedo F. Dermatitis artefacta. Dermatol Online J 2021; 27:13030/qt7p92b04t. [PMID: 33865294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Accepted: 04/12/2021] [Indexed: 06/12/2023] Open
Affiliation(s)
- A Cerejeira
- Department of Dermatology and Venereology, Centro Hospitalar São João, EPE Porto.
| | | | | | | | | |
Collapse
|
23
|
Cerejeira A, Gomes N, Cruz M, Mota A, Azevedo F. Dermatitis artefacta. Dermatol Online J 2021. [DOI: 10.5070/d3273052787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
24
|
Rodríguez M, Ruiz A, Piedra L, Gutierrez G, Rey J, Cruz M, Bisset J. Multiple insecticide resistance in Aedes aegypti (Diptera: Culicidae) from Boyeros municipality, Cuba and associated mechanisms. Acta Trop 2020; 212:105680. [PMID: 32866457 DOI: 10.1016/j.actatropica.2020.105680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 08/07/2020] [Accepted: 08/25/2020] [Indexed: 10/23/2022]
Abstract
In this study, insecticide resistance and the mechanisms responsible were characterized in Ae. aegypti of Boyeros municipality from Havana, Cuba. Boyeros represents a high epidemiological risk because it is located near the Havana International Airport, it is highly urbanized, and it has a large influx of people from endemic countries so that it qualifies as a sentinel site for surveillance. The larvae collected from five areas of this municipality showed resistance to temephos associated with metabolic enzymes. The adult mosquitoes displayed a deltamethrin resistance and less distinctly to other pyrethroids associated with a high frequency of sodium channel gene mutations (F1534C and V1016I), detected for the first time in a field population from Cuba. The presence in the field populations of two insecticide resistance mechanisms represents a limiting factor in the success of the control operations of this vector, so other strategies should be considered to preserve the effectiveness of the insecticides available in public health for vector control in Cuba.
Collapse
|
25
|
Dias Ferreira Reis J, Ramos R, Modas Daniel P, Aguiar Rosa S, Almeida Morais L, Cruz M, Moreira R, Mendonca T, Monteiro A, Leal C, Marques H, Figueiredo L, Cruz Ferreira R. Optimizing diagnosis of obstructive coronary artery disease by CT angiography: RCT's final results and 12-months follow-up. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Aim
In patients (pts) with suspected coronary artery disease (CAD), computed tomographic angiography (CTA) may improve pt selection for invasive coronary angiography (ICA) as alternative to functional testing. However. the role of CTA in symptomatic pts after abnormal functional test (FT) is incompletely defined.
Methods and results
This randomized clinical trial conducted in single academic tertiary center selected 218 symptomatic pts with mild to moderately abnormal FT referred to ICA to receive either the originally intended ICA (n=103) or CTA (n=115). CTA interpretation and subsequent care decisions were made by the clinical team. Pts with high risk features on FT, previous acute coronary syndrome, previously documented CAD, chronic kidney disease (GFR<60ml/min/1.73m2) or persistent atrial fibrillation were excluded. The primary endpoint was the percentage of ICA with no significant obstructive CAD (no stenosis ≥50%) in each group. Diagnostic (DY) and revascularization (RY) yields of ICA in either group were also assessed. Pts were followed up for at least 1 year for the primary safety endpoint of all cause death/ nonfatal myocardial infarction/ stroke. Unplanned revascularization
(UP) and symptomatic status (SS) were also evaluated. Pts averaged 68±9 years of age, 60% were male, 29% were diabetic. Nuclear perfusion stress test was used in 33.9% in CTA group and 31.1% in control group (p=0.655). Mean post (functional) test probability of obstructive CAD was 34%. Overall prevalence of obstructive CAD was 32.1%. In the CTA group, ICA was cancelled by referring physicians in 83 of the pts (72.2%) after receiving CTA results. For those undergoing ICA, non-obstructive
CAD was found in 5 pts (15.6%) in the CTA-guided arm and 60 (58.3%) in the usual care arm (p<0.001 Mean cumulative radiation exposure related to diagnostic work up was similar in both groups (6±14 vs 5±14mSv, p=0.152). Both DY (84.4% vs 41.7, p<0.001) and RY (71.9% vs 38.8%, p=0.001) yields were significantly higher for CTA-guided ICA as compared to standard FT-guided ICA. The rate of the primary safety endpoint was similar between both groups (1.9% vs 0%, p=0.244), as well as the rates of UP (0.9% vs 0.9%, p=1.000) and SS (persistent angina: 29.6% vs 24.8%, p=0.425).
Conclusions
In pts with suspected CAD and mild to moderately abnormal ischemia test, a diagnostic strategy including CTA as gatekeeper is safe, effective and significantly improves diagnostic and revascularization yields of ICA.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - R Ramos
- Hospital de Santa Marta, Lisbon, Portugal
| | | | | | | | - M Cruz
- Hospital de Santa Marta, Lisbon, Portugal
| | - R Moreira
- Hospital de Santa Marta, Lisbon, Portugal
| | - T Mendonca
- Hospital de Santa Marta, Lisbon, Portugal
| | - A Monteiro
- Hospital de Santa Marta, Lisbon, Portugal
| | - C Leal
- Hospital de Santa Marta, Radiology Department, Lisbon, Portugal
| | - H Marques
- Hospital de Santa Marta, Radiology Department, Lisbon, Portugal
| | - L Figueiredo
- Hospital de Santa Marta, Radiology Department, Lisbon, Portugal
| | | |
Collapse
|
26
|
Trindade NM, Cruz MR, Yoshimura EM. Correlation between thermoluminescence and optically stimulated luminescence responses of natural alexandrite. Appl Radiat Isot 2020; 166:109402. [PMID: 32911438 DOI: 10.1016/j.apradiso.2020.109402] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 08/11/2020] [Accepted: 08/27/2020] [Indexed: 11/28/2022]
Abstract
Luminescent properties of alexandrite crystals (BeAl2O4:Cr3+) are studied. Partial readouts of thermoluminescence (TL) and optically stimulated luminescence (OSL) signals were obtained to infer the relations of OSL and TL trapping centers. Four TL peaks were studied; their intensities decrease at different rates by illumination with blue OSL light. The OSL curve shows two-time components (exponential decay constants 3.15 and 28.4 s). The short time component is preferentially diminished when the sample is heated to temperatures from 363 to 513 K. About 50% of the whole TL intensity remains after a complete 300s OSL readout.
Collapse
Affiliation(s)
- N M Trindade
- Department of Physics, Federal Institute of Education, Science and Technology of São Paulo, IFSP, São Paulo, SP, Brazil; Institute of Physics, University of São Paulo - USP, São Paulo, SP, Brazil.
| | - M R Cruz
- Institute of Physics, University of São Paulo - USP, São Paulo, SP, Brazil
| | - E M Yoshimura
- Institute of Physics, University of São Paulo - USP, São Paulo, SP, Brazil
| |
Collapse
|
27
|
Sendino O, Loras C, Mata A, Momblán D, Andujar X, Cruz M, Cárdenas A, Marquez I, Uchima H, Cordova H, de Lacy AM, Espinós J. Safety and efficacy of endoscopic vacuum therapy for the treatment of perforations and anastomotic leaks of the upper gastrointestinal tract. Gastroenterol Hepatol 2020; 43:431-438. [PMID: 32680732 DOI: 10.1016/j.gastrohep.2020.01.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 01/19/2020] [Accepted: 01/23/2020] [Indexed: 12/24/2022]
Abstract
AIM To evaluate the efficacy and safety of endoscopic vacuum therapy (EVT) in the management of perforations and anastomotic leaks of the upper gastrointestinal tract. PATIENTS AND METHODS This is a retrospective observational study which included patients who underwent EVT due to any upper gastrointestinal defect between April 2017 and February 2019 in three Spanish Hospitals. To this end, we used the only medical device approved to date for endoscopic use (Eso-SPONGEr; B. Braun Melsungen AG, Melsungen, Germany). RESULTS 11 patients were referred for EVT of an anastomotic leak after esophagectomy (n=7), gastrectomy (n=2), esophageal perforation secondary to endoscopic Zenker's septomiotomy (n=1) and Boerhaave syndrome (n=1). The median size of the cavity was 8×3cm. The median delay between surgery and EVT was 7 days. The median of EVT duration was 28 days. The median number of sponges used was 7 and the mean period replacement was 3.7 days. In 10 cases (91%), the defect was successfully closed. In 9 cases (82%) clinical resolution of the septic condition was achieved. 5 patients presented some adverse event: 3 anastomotic strictures, 1 retropharyngeal pain and 1 case of new-onset pneumonia. The median hospital stay from the start of EVT was 45 days. 1 patient died owing to septic complications secondary to the anastomotic leak. CONCLUSION EVT was successful in over 90% of perforations and anastomotic leaks of the upper gastrointestinal tract. Moreover, this is a safe therapy with only mild adverse events associated.
Collapse
Affiliation(s)
- O Sendino
- Unidad de Endoscopia, Servicio de Gastroenterología, ICMDiM, IDIBAPS, CIBEREHD, Hospital Clínic, Universitat de Barcelona, Barcelona, España.
| | - C Loras
- Servicio Digestivo, Hospital Universitari Mútua de Terrassa, Terrassa, España
| | - A Mata
- Unidad de Endoscopia, Departamento de Gastroenterología, Centro Médico Teknon, Barcelona, España
| | - D Momblán
- Servicio de Cirugía Gastrointestinal, ICMDiM, Hospital Clínic, Universitat de Barcelona, Barcelona, España
| | - X Andujar
- Servicio Digestivo, Hospital Universitari Mútua de Terrassa, Terrassa, España
| | - M Cruz
- Unidad de Endoscopia, Departamento de Gastroenterología, Centro Médico Teknon, Barcelona, España
| | - A Cárdenas
- Unidad de Endoscopia, Servicio de Gastroenterología, ICMDiM, IDIBAPS, CIBEREHD, Hospital Clínic, Universitat de Barcelona, Barcelona, España
| | - I Marquez
- Servicio Digestivo, Hospital Universitari Mútua de Terrassa, Terrassa, España
| | - H Uchima
- Unidad de Endoscopia, Departamento de Gastroenterología, Centro Médico Teknon, Barcelona, España
| | - H Cordova
- Unidad de Endoscopia, Servicio de Gastroenterología, ICMDiM, IDIBAPS, CIBEREHD, Hospital Clínic, Universitat de Barcelona, Barcelona, España
| | - A M de Lacy
- Servicio de Cirugía Gastrointestinal, ICMDiM, IDIBAPS, CIBEREHD, AIS Channel, Hospital Clínic, Universitat de Barcelona, Barcelona, España
| | - J Espinós
- Servicio Digestivo, Hospital Universitari Mútua de Terrassa, Terrassa, España; Unidad de Endoscopia, Departamento de Gastroenterología, Centro Médico Teknon, Barcelona, España
| |
Collapse
|
28
|
Pimentel T, Ritto F, Canellas JV, Junger B, Cruz M, Medeiros PJ. Re: Randomized double-blind clinical trial evaluation of bone healing after third molar surgery with the use of leukocyte- and platelet-rich fibrin. Int J Oral Maxillofac Surg 2019; 49:692. [PMID: 31757693 DOI: 10.1016/j.ijom.2019.10.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Revised: 09/06/2019] [Accepted: 10/24/2019] [Indexed: 10/25/2022]
Affiliation(s)
- T Pimentel
- Department of Oral and Maxillofacial Surgery, Faculty of Odontology, Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil.
| | - F Ritto
- Department of Oral and Maxillofacial Surgery, Faculty of Odontology, Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil
| | - J V Canellas
- Department of Oral and Maxillofacial Surgery, Faculty of Odontology, Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil
| | - B Junger
- Department of Oral and Maxillofacial Surgery, Faculty of Odontology, Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil
| | - M Cruz
- Department of Oral and Maxillofacial Surgery, Faculty of Odontology, Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil
| | - P J Medeiros
- Department of Oral and Maxillofacial Surgery, Faculty of Odontology, Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil
| |
Collapse
|
29
|
De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D, De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D, Kotseva K, De Backer G, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro Conde A, Cifkova R, Crowley J, Davletov K, Bacquer DD, De Smedt D, De Sutter J, Deckers J, Dilic M, Dolzhenko M, Druais H, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N, Grobbee D, Gyberg V, Hasan Ali H, Heuschmann P, Hoes A, Jankowski P, Lalic N, Lehto S, Lovic D, Maggioni A, Mancas S, Marques-Vidal P, Mellbin L, Miličić D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Ž, Rydén L, Stagmo M, Störk S, Sundvall J, Tokgözoğlu L, Tsioufis K, Vulic D, Wood D, Wood D, Kotseva K, Jennings C, Adamska A, Adamska S, Rydén L, Mellbin L, Tuomilehto J, Schnell O, Druais H, Fiorucci E, Glemot M, Larras F, Missiamenou V, Maggioni A, Taylor C, Ferreira T, Lemaitre K, Bacquer DD, De Backer G, Raman L, Sundvall J, DeSmedt D, De Sutter J, Willems A, De Pauw M, Vervaet P, Bollen J, Dekimpe E, Mommen N, Van Genechten G, Dendale P, Bouvier C, Chenu P, Huyberechts D, Persu A, Dilic M, Begic A, Durak Nalbantic A, Dzubur A, Hadzibegic N, Iglica A, Kapidjic S, Osmanagic Bico A, Resic N, Sabanovic Bajramovic N, Zvizdic F, Vulic D, Kovacevic-Preradovic T, Popovic-Pejicic S, Djekic D, Gnjatic T, Knezevic T, Kovacevic-Preradovic T, Kos L, Popovic-Pejicic S, Stanetic B, Topic G, Gotcheva N, Georgiev B, Terziev A, Vladimirov G, Angelov A, Kanazirev B, Nikolaeva S, Tonkova D, Vetkova M, Milicic D, Reiner Ž, Bosnic A, Dubravcic M, Glavina M, Mance M, Pavasovic S, Samardzic J, Batinic T, Crljenko K, Delic-Brkljacic D, Dula K, Golubic K, Klobucar I, Kordic K, Kos N, Nedic M, Olujic D, Sedinic V, Blazevic T, Pasalic A, Percic M, Sikic J, Bruthans J, Cífková R, Hašplová K, Šulc P, Wohlfahrt P, Mayer O, Cvíčela M, Filipovský J, Gelžinský J, Hronová M, Hasan-Ali H, Bakery S, Mosad E, Hamed H, Ibrahim A, Elsharef M, Kholef E, Shehata A, Youssef M, Elhefny E, Farid H, Moustafa T, Sobieh M, Kabil H, Abdelmordy A, Lehto S, Kiljander E, Kiljander P, Koukkunen H, Mustonen J, Cremer C, Frantz S, Haupt A, Hofmann U, Ludwig K, Melnyk H, Noutsias M, Karmann W, Prondzinsky R, Herdeg C, Hövelborn T, Daaboul A, Geisler T, Keller T, Sauerbrunn D, Walz-Ayed M, Ertl G, Leyh R, Störk S, Heuschmann P, Ehlert T, Klocke B, Krapp J, Ludwig T, Käs J, Starke C, Ungethüm K, Wagner M, Wiedmann S, Tsioufis K, Tolis P, Vogiatzi G, Sanidas E, Tsakalis K, Kanakakis J, Koutsoukis A, Vasileiadis K, Zarifis J, Karvounis C, Crowley J, Gibson I, Houlihan A, Kelly C, O'Donnell M, Bennati M, Cosmi F, Mariottoni B, Morganti M, Cherubini A, Di Lenarda A, Radini D, Ramani F, Francese M, Gulizia M, Pericone D, Davletov K, Aigerim K, Zholdin B, Amirov B, Assembekov B, Chernokurova E, Ibragimova F, Kodasbayev A, Markova A, Mirrakhimov E, Asanbaev A, Toktomamatov U, Tursunbaev M, Zakirov U, Abilova S, Arapova R, Bektasheva E, Esenbekova J, Neronova K, Asanbaev A, Baigaziev K, Toktomamatov U, Zakirov U, Baitova G, Zheenbekov T, Erglis A, Andrejeva T, Bajare I, Kucika G, Labuce A, Putane L, Stabulniece M, Dzerve V, Klavins E, Sime I, Badariene J, Gedvilaite L, Pečiuraite D, Sileikienė V, Skiauteryte E, Solovjova S, Sidabraite R, Briedis K, Ceponiene I, Jurenas M, Kersulis J, Martinkute G, Vaitiekiene A, Vasiljevaite K, Veisaite R, Plisienė J, Šiurkaitė V, Vaičiulis Ž, Jankowski P, Czarnecka D, Kozieł P, Podolec P, Nessler J, Gomuła P, Mirek-Bryniarska E, Bogacki P, Wiśniewski A, Pająk A, Wolfshaut-Wolak R, Bućko J, Kamiński K, Łapińska M, Paniczko M, Raczkowski A, Sawicka E, Stachurska Z, Szpakowicz M, Musiał W, Dobrzycki S, Bychowski J, Kosior D, Krzykwa A, Setny M, Kosior D, Rak A, Gąsior Z, Haberka M, Gąsior Z, Haberka M, Szostak-Janiak K, Finik M, Liszka J, Botelho A, Cachulo M, Sousa J, Pais A, Aguiar C, Durazzo A, Matos D, Gouveia R, Rodrigues G, Strong C, Guerreiro R, Aguiar J, Abreu A, Cruz M, Daniel P, Morais L, Moreira R, Rosa S, Rodrigues I, Selas M, Gaita D, Mancas S, Apostu A, Cosor O, Gaita L, Giurgiu L, Hudrea C, Maximov D, Moldovan B, Mosteoru S, Pleava R, Ionescu M, Parepa I, Pogosova N, Arutyunov A, Ausheva A, Isakova S, Karpova A, Salbieva A, Sokolova O, Vasilevsky A, Pozdnyakov Y, Antropova O, Borisova L, Osipova I, Lovic D, Aleksic M, Crnokrak B, Djokic J, Hinic S, Vukasin T, Zdravkovic M, Lalic N, Jotic A, Lalic K, Lukic L, Milicic T, Macesic M, Stanarcic Gajovic J, Stoiljkovic M, Djordjevic D, Kostic S, Tasic I, Vukovic A, Fras Z, Jug B, Juhant A, Krt A, Kugonjič U, Chipayo Gonzales D, Gómez Barrado J, Kounka Z, Marcos Gómez G, Mogollón Jiménez M, Ortiz Cortés C, Perez Espejo P, Porras Ramos Y, Colman R, Delgado J, Otero E, Pérez A, Fernández-Olmo M, Torres-LLergo J, Vasco C, Barreñada E, Botas J, Campuzano R, González Y, Rodrigo M, de Pablo C, Velasco E, Hernández S, Lozano C, González P, Castro A, Dalmau R, Hernández D, Irazusta F, Vélez A, Vindel C, Gómez-Doblas J, García Ruíz V, Gómez L, Gómez García M, Jiménez-Navarro M, Molina Ramos A, Marzal D, Martínez G, Lavado R, Vidal A, Rydén L, Boström-Nilsson V, Kjellström B, Shahim B, Smetana S, Hansen O, Stensgaard-Nake E, Deckers J, Klijn A, Mangus T, Peters R, Scholte op Reimer W, Snaterse M, Aydoğdu S, Ç Erol, Otürk S, Tulunay Kaya C, Ahmetoğlu Y, Ergene O, Akdeniz B, Çırgamış D, Akkoyun H Kültürsay S, Kayıkçıoğlu M, Çatakoğlu A, Çengel A, Koçak A, Ağırbaşlı M, Açıksarı G, Çekin M, Tokgözoğlu L, Kaya E, Koçyiğit D, Öngen Z, Özmen E, Sansoy V, Kaya A, Oktay V, Temizhan A, Ünal S, İ Yakut, Kalkan A, Bozkurt E, Kasapkara H, Dolzhenko M, Faradzh C, Hrubyak L, Konoplianyk L, Kozhuharyova N, Lobach L, Nesukai V, Nudchenko O, Simagina T, Yakovenko L, Azarenko V, Potabashny V, Bazylevych A, Bazylevych M, Kaminska K, Panchenko L, Shershnyova O, Ovrakh T, Serik S, Kolesnik T, Kosova H, Wood D, Adamska A, Adamska S, Jennings C, Kotseva K, Hoye P Atkin A, Fellowes D, Lindsay S, Atkinson C, Kranilla C, Vinod M, Beerachee Y, Bennett C, Broome M, Bwalya A, Caygill L, Dinning L, Gillespie A, Goodfellow R, Guy J, Idress T, Mills C, Morgan C, Oustance N, Singh N, Yare M, Jagoda J, Bowyer H, Christenssen V, Groves A, Jan A, Riaz A, Gill M, Sewell T, Gorog D, Baker M, De Sousa P, Mazenenga T, Porter J, Haines F, Peachey T, Taaffe J, Wells K, Ripley D, Forward H, McKie H, Pick S, Thomas H, Batin P, Exley D, Rank T, Wright J, Kardos A, Sutherland SB, Wren L, Leeson P, Barker D, Moreby B, Sawyer J, Stirrup J, Brunton M, Brodison A, Craig J, Peters S, Kaprielian R, Bucaj A, Mahay K, Oblak M, Gale C, Pye M, McGill Y, Redfearn H, Fearnley M. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285:135-146. [DOI: 10.1016/j.atherosclerosis.2019.03.014] [Citation(s) in RCA: 101] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 02/22/2019] [Accepted: 03/19/2019] [Indexed: 12/16/2022]
|
30
|
Sousa C, Pinto L, Cruz M, Neto A, Bastos J, Miranda C, Melo G, Khouri L, Figueiredo P, Alves P. EP-1327 Impact of neoadjuvant radiotherapy in locally advanced breast carcinoma. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31747-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Sousa C, Cruz M, Pereira K, Neto A, Gonçalves S, Brandão J, Khouri L, Alves C, Alves P. EP-2148 Brachytherapy on anal canal tumors. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32568-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Fernández-Aceñero MJ, Cruz M, Sastre-Varela J, Casal JI, Nieto MAC, Del Puerto-Nevado L, García-Foncillas J, Cebrián A. TRIM72 Immunohistochemical Expression Can Predict Relapse in Colorectal Carcinoma. Pathol Oncol Res 2019; 26:861-865. [PMID: 30852740 DOI: 10.1007/s12253-019-00629-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 03/01/2019] [Indexed: 10/27/2022]
Abstract
Large bowel adenocarcinoma is one of the most frequent human neoplasms and despite recent insights into the pathophysiology and molecular basis of this disease, mortality remains high in advanced and metastatic cases. Most guidelines recommend adjuvant chemotherapy for tumours involving lymph nodes, but not for patients with localized stage I or II disease. However, it is well known that approximately 20% of stage II colorectal carcinoma patients eventually recur, mainly with distant or peritoneal involvement and show bad prognosis. It would be important to predict which patients are at increased risk of recurrence to guide potential adjuvant therapy use in this controversial setting. In this sense, only microsatellite stability has been proposed as a predictive tool in some guidelines. The tripartite motif family protein 72 (TRIM72) is a ubiquitin ligase, involved in the cell membrane repair machinery and known to be associated to insulin resistance. Its potential role in colon cancer has recently been proposed. The aim of this study is to determine the potential predictive value of TRIM72 immunohistochemical expression in stage II colon carcinoma. We have retrospectively reviewed a series of 95 patients with stage II colon microsatellite stable carcinomas operated with a curative intent at a single large tertiary hospital in Madrid (Spain) between 2006 and 2012. None of the patients received adjuvant chemotherapy. We reviewed the histopathological slides and constructed a tissue microarray (TMA) of three representative areas to perform immunohistochemical staining for TRIM72. In our series 30 patients (31.7%) recurred after a median follow-up of 17.5 months. Lack of immunohistochemical expression of TRIM72 in the tumor was significantly and independently associated to recurrence. A recent report by Chen et al. has shown that TRIM72 can be measured in plasma for colon carcinoma detection as an alternative to CEA or CA19.9, with lower levels in patients with carcinoma. Our report is the first one to show that lower immunohistochemical expression of TRIM72 predicts recurrence in colon stage II carcinoma. We feel this predictive influence can be related to its crucial role as a central regulator in many signaling pathways (PI3K-AKT, ERK). As an ubiquitin ligase, the lack of TRIM72 could increase the levels of several potential oncogenic molecules and therefore lead to a more aggressive phenotype. It remains to be shown whether chemotherapy could change the clinical behaviour of this bad prognosis group. We propose TRIM72 immunohistochemical analysis as a potential tool to predict recurrence risk in stage II colon carcinoma patients. Our results should be confirmed in larger series, but could open the way to management strategies refinement in this early stage group of patients.
Collapse
Affiliation(s)
- M J Fernández-Aceñero
- Department of Surgical Pathology, Hospital Clínico San Carlos, Avda Profesor Martín Lagos s, /n 28040, Madrid, Spain.
| | - M Cruz
- Translational Investigation, Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - J Sastre-Varela
- Departments of Oncology, Hospital Clínico San Carlos, Madrid, Spain
| | - J I Casal
- Centro de Investigaciones Biológicas (CIB), Madrid, Spain
| | - M A Cerón Nieto
- Department of Surgical Pathology, Hospital Clínico San Carlos, Avda Profesor Martín Lagos s, /n 28040, Madrid, Spain
| | | | - J García-Foncillas
- Translational Investigation, Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - A Cebrián
- Translational Investigation, Hospital Fundación Jiménez Díaz, Madrid, Spain
| |
Collapse
|
33
|
Berry M, Jenner E, Plummer S, Cruz M, Harper S. Early doors: can emergency care therapies help to prevent avoidable admissions in the Emergency Department? Physiotherapy 2019. [DOI: 10.1016/j.physio.2018.11.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
34
|
Giles J, Cruz M, González-Ravina C, Caligara C, Prados N, Martínez JC, Vergara V, Requena A. Small-sized follicles could contribute to high-order multiple pregnancies: outcomes of 6552 intrauterine insemination cycles. Reprod Biomed Online 2018; 37:549-554. [PMID: 30482725 DOI: 10.1016/j.rbmo.2018.08.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Revised: 08/20/2018] [Accepted: 08/21/2018] [Indexed: 11/17/2022]
Abstract
RESEARCH QUESTION Can predictors of twin and high-order multiple pregnancy among women with multiple cycles of ovarian stimulation intrauterine insemination (IUI) be identified? DESIGN Retrospective cohort study of IUI cycles carried out between January 2014 and December 2015 in a private clinic in Spain. The 4879 women and 6552 cycles analysed in this study include single IUI with ovarian stimulation using recombinant FSH. RESULTS Number of follicles and follicle size were the only factors with a significant effect (P < 0.001) on the likelihood of achieving a twin or multifetal pregnancy. Follicles 12 mm or wider greatly increase the chances of achieving a twin or multifetal pregnancy. A total of 73 out of 127 (57.5%) twin pregnancies occurred in cycles with at least one additional follicle measuring 12 mm or wider, and 102 out of 127 twin pregnancies (80.3%) occurred in cycles with at least one additional follicle measuring 14 mm or wider. Cancellation criteria should consider the presence of follicles 12 mm or wider. CONCLUSION Follicles measuring 12 mm or wider increase the risk of having a twin or a high-order multiple pregnancy rate. These data may help clinicians balance decision-making between cancelling and performing the cycle within an IUI procedure.
Collapse
Affiliation(s)
- J Giles
- Reproductive Medicine Department, Instituto Valenciano de Infertilidad IVI Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.
| | - M Cruz
- Reproductive Medicine Department, Instituto Valenciano de Infertilidad IVI Madrid, Avenida del Talgo 68-70, Aravaca, Madrid 28023
| | - C González-Ravina
- Reproductive Medicine Department, Instituto Valenciano de Infertilidad (IVI) Sevilla, Avenida de la República Argentina 58, Sevilla 41011, Spain
| | - C Caligara
- Reproductive Medicine Department, Instituto Valenciano de Infertilidad (IVI) Sevilla, Avenida de la República Argentina 58, Sevilla 41011, Spain
| | - N Prados
- Reproductive Medicine Department, Instituto Valenciano de Infertilidad (IVI) Sevilla, Avenida de la República Argentina 58, Sevilla 41011, Spain
| | - J C Martínez
- Reproductive Medicine Department, Instituto Valenciano de Infertilidad (IVI) Murcia, Calle Navegante Macías del Poyo, 5 - Edificio Delfín - Barrio La Flota, Murcia 30007, Spain
| | - V Vergara
- Reproductive Medicine Department, Instituto Valenciano de Infertilidad IVI Madrid, Avenida del Talgo 68-70, Aravaca, Madrid 28023
| | - A Requena
- Reproductive Medicine Department, Instituto Valenciano de Infertilidad IVI Madrid, Avenida del Talgo 68-70, Aravaca, Madrid 28023
| |
Collapse
|
35
|
Park L, Chang S, Ko T, Rhee K, Anker J, Bhave M, Davis A, Cruz M, Iams W, Zou L, Wang V, Chuang J, Chae Y. P1.04-01 Impact of Chromatin Remodeling Genes Including SMARCA2 and PBRM1 on Neoantigen and Immune Landscape of NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Chae Y, Chang S, Ko T, Rhee K, Cruz M, Bhave M, Anker J, Davis A, Iams W, Wang V, Chuang J, Park L. P1.04-25 The Implication of Frameshift Mutation Burden in Neoantigen and Immune Cell Landscape in Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Timoteo AT, Moura Branco L, Galrinho A, Cruz M, Ilhao Moreira R, Feliciano J, Abreu J, Rio P, Portugal G, Cruz Ferreira R. P3504Cardiotoxicity and left ventricular function: what about diastolic function? Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A T Timoteo
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | | | - A Galrinho
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - M Cruz
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | | | - J Feliciano
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - J Abreu
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - P Rio
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - G Portugal
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | | |
Collapse
|
38
|
Apitz-Castro R, Fonseca G, Michelena V, Cruz MR. Inhibition of the Platelet Reaction by a High Molecular Weight Phosphoglycoprotein Isolated from Human Platelet Plasma Membranes. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe effect of a phospho-glycoprotein (HMW-GP), obtained from human platelet plasma membranes, on the aggregation and secretion of human platelets was studied. Incubation of PRP with 4 to 16 μg/ml of HMW-GP results in inhibition of ADP-, Epinephrine-, Collagen-, and Thrombin-induced platelet aggregation. The effect is mainly reflected on the secondary wave of aggregation. The inhibitory effect is partially overcome by higher concentration of the inducers, however, even under these conditions, a clear tendency towards disaggregation is observed. 5HT release (Col-induced) is strongly decreased from 50% to 4.5. The inhibitory effect on Thrombin-induced aggregation is markedly dependent on external calcium, being maximal at 5 mM calcium. The HMW-GP does not bind ADP or Thrombin. Membrane conformation is markedly affected, as evidenced by the effect of HMW-GP on the iodination of surface polypeptides of intact platelets. It is suggested that interaction of HMW-GP with the platelet membrane blocks the signal(s) transmission that links stimulus to activation. The inhibition observed might just represent an experimental amplification of the endogenous modulatory function that has been proposed for this high molecular weight phosphoglycoprotein.
Collapse
Affiliation(s)
- R Apitz-Castro
- The Centro de Biofisica y Bioquimica, Instituto Venezolano de Investigaciones Cientificas (IVIC), Caracas, Venezuela
| | - G Fonseca
- The Centro de Biofisica y Bioquimica, Instituto Venezolano de Investigaciones Cientificas (IVIC), Caracas, Venezuela
| | - V Michelena
- The Centro de Biofisica y Bioquimica, Instituto Venezolano de Investigaciones Cientificas (IVIC), Caracas, Venezuela
| | - M R Cruz
- The Centro de Biofisica y Bioquimica, Instituto Venezolano de Investigaciones Cientificas (IVIC), Caracas, Venezuela
| |
Collapse
|
39
|
Cruz M, Barros R, Martins J, Roriz J, Pinto M, Carneiro A. Stroke-like migraine attacks after radiation therapy : qu’est-ce que c’est ? Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.03.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
40
|
Castelán-Martínez OD, Hoyo-Vadillo C, Bazán-Soto TB, Cruz M, Tesoro-Cruz E, Valladares-Salgado A. CYP2C9*3
gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide. J Clin Pharm Ther 2018; 43:768-774. [DOI: 10.1111/jcpt.12710] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Accepted: 04/16/2018] [Indexed: 11/30/2022]
Affiliation(s)
- O. D. Castelán-Martínez
- Facultad de Estudios Superiores Zaragoza; Universidad Nacional Autónoma de México; Mexico City Mexico
| | - C. Hoyo-Vadillo
- Departamento de Farmacología; Centro de Investigación y Estudios Avanzados del IPN; Mexico City Mexico
| | - T. B. Bazán-Soto
- Facultad de Estudios Superiores Zaragoza; Universidad Nacional Autónoma de México; Mexico City Mexico
| | - M. Cruz
- Unidad de Investigación Médica en Bioquímica; Centro Médico Nacional Siglo XXI IMSS; Mexico City Mexico
| | - E. Tesoro-Cruz
- Unidad de Investigación Médica en Inmunología e Infectología; Centro Médico Nacional La Raza; Mexico City Mexico
| | - A. Valladares-Salgado
- Unidad de Investigación Médica en Bioquímica; Centro Médico Nacional Siglo XXI IMSS; Mexico City Mexico
| |
Collapse
|
41
|
Sousa C, Pinto L, Saraiva N, Rego I, Paulo J, Bastos J, Mariano M, Sousa G, Roda D, Miranda C, Melo G, Cruz M, Martins S, Kayla P. EP-1353: Breast Cancer In Young Women: A Retrospective Study. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31662-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Gioia GV, Vinueza RL, Marsot M, Devillers E, Cruz M, Petit E, Boulouis HJ, Moutailler S, Monroy F, Coello MA, Gondard M, Bournez L, Haddad N, Zanella G. Bovine anaplasmosis and tick-borne pathogens in cattle of the Galapagos Islands. Transbound Emerg Dis 2018; 65:1262-1271. [PMID: 29566306 DOI: 10.1111/tbed.12866] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Indexed: 10/17/2022]
Abstract
A cross-sectional study was conducted to determine the species of Anaplasma spp. and estimate its prevalence in cattle of the three main cattle-producing Galapagos Islands (Santa Cruz, San Cristóbal and Isabela) using indirect PCR assays, genetic sequencing and ELISA. Ticks were also collected from cattle and scanned for 47 tick-borne pathogens in a 48 × 48 real-time PCR chip. A mixed effects logistic regression was performed to identify potential risk factors explaining Anaplasma infection in cattle. A. phagocytophilum was not detected in any of the tested animals. Genetic sequencing allowed detection of A. platys-like strains in 11 (36.7%) of the 30 Anaplasma spp.-positive samples analysed. A. marginale was widespread in the three islands with a global between-herd prevalence of 100% [89; 100]95% CI and a median within-herd prevalence of 93%. A significant association was found between A. marginale infection and age with higher odds of being positive for adults (OR = 3.3 [1.2; 9.9]95% Bootstrap CI ). All collected ticks were identified as Rhipicephalus microplus. A. marginale, Babesia bigemina, Borrelia theileri and Francisella-like endosymbiont were detected in tick pools. These results show that the Galapagos Islands are endemic for A. marginale.
Collapse
Affiliation(s)
- G V Gioia
- Epidemiology Unit, Laboratory for Animal Health, ANSES, University Paris Est, Maisons-Alfort, France.,UBL, MAN-IMAL IDEFI ANR 11-0003, Atlantic National College of Veterinary Medicine, Food Science and Engineering (Oniris), Nantes, France
| | - R L Vinueza
- Universidad San Francisco de Quito (USFQ), Escuela de Medicina Veterinaria, Quito, Ecuador
| | - M Marsot
- Epidemiology Unit, Laboratory for Animal Health, ANSES, University Paris Est, Maisons-Alfort, France
| | - E Devillers
- UMR BIPAR, Laboratory for Animal Health, ANSES, INRA, Ecole Nationale Vétérinaire d'Alfort, University Paris-Est, Maisons-Alfort, France
| | - M Cruz
- Agencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos (ABG), Puerto Ayora, Ecuador
| | - E Petit
- UMR BIPAR, Laboratory for Animal Health, ANSES, INRA, Ecole Nationale Vétérinaire d'Alfort, University Paris-Est, Maisons-Alfort, France
| | - H J Boulouis
- UMR BIPAR, Laboratory for Animal Health, ANSES, INRA, Ecole Nationale Vétérinaire d'Alfort, University Paris-Est, Maisons-Alfort, France
| | - S Moutailler
- UMR BIPAR, Laboratory for Animal Health, ANSES, INRA, Ecole Nationale Vétérinaire d'Alfort, University Paris-Est, Maisons-Alfort, France
| | - F Monroy
- Universidad San Francisco de Quito (USFQ), Escuela de Medicina Veterinaria, Quito, Ecuador
| | - M A Coello
- Universidad San Francisco de Quito (USFQ), Escuela de Medicina Veterinaria, Quito, Ecuador
| | - M Gondard
- UMR BIPAR, Laboratory for Animal Health, ANSES, INRA, Ecole Nationale Vétérinaire d'Alfort, University Paris-Est, Maisons-Alfort, France
| | - L Bournez
- Nancy Laboratory for Rabies and Wildlife, ANSES, Nancy, France
| | - N Haddad
- UMR BIPAR, Laboratory for Animal Health, ANSES, INRA, Ecole Nationale Vétérinaire d'Alfort, University Paris-Est, Maisons-Alfort, France
| | - G Zanella
- Epidemiology Unit, Laboratory for Animal Health, ANSES, University Paris Est, Maisons-Alfort, France
| |
Collapse
|
43
|
Monteiro A, Cunha P, Oliveira M, Cruz M, Aguiar S, Morais L, Portugal G, Valente B, Osorio P, Lousinha A, Malveira P, Santos A, Ferreira R. P392Assessment of novel oral anticoagulant use in real-world setting: importance of a structured anticoagulation unit. Europace 2018. [DOI: 10.1093/europace/euy015.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Monteiro
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - P Cunha
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - M Oliveira
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - M Cruz
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - S Aguiar
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - L Morais
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - G Portugal
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - B Valente
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - P Osorio
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - A Lousinha
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - P Malveira
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - A Santos
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| | - R Ferreira
- Hospital Santa Marta, Department of Cardiology, Lisbon, Portugal
| |
Collapse
|
44
|
Oliveira MM, Cunha PS, Valente B, Silva N, Portugal G, Cruz M, Monteiro N, Delgado AS, Pereira M, Ferreira RC. P839Long-term follow-up after atrial fibrillation ablation using 3D high-density voltage mapping with a single-puncture approach. Europace 2018. [DOI: 10.1093/europace/euy015.442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - P S Cunha
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - B Valente
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - N Silva
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - G Portugal
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - M Cruz
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - N Monteiro
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - A S Delgado
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | - M Pereira
- Hospital Santa Marta, CHLC, Lisbon, Portugal
| | | |
Collapse
|
45
|
Valbom Mesquita D, Cunha PS, Valente BT, Nogueira Silva M, Cruz M, Portugal G, Delgado AS, Alves MT, Carlos I, Cruz Ferreira R, Oliveira MM. P831Atrial tachyarrhythmias during the blanking period after ablation of atrial fibrillation: a predictor of long-term recurrence. Europace 2018. [DOI: 10.1093/europace/euy015.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - P S Cunha
- Hospital de Santa Marta, Lisbon, Portugal
| | | | | | - M Cruz
- Hospital de Santa Marta, Lisbon, Portugal
| | - G Portugal
- Hospital de Santa Marta, Lisbon, Portugal
| | | | - M T Alves
- Hospital de Santa Marta, Lisbon, Portugal
| | - I Carlos
- Hospital de Santa Marta, Lisbon, Portugal
| | | | | |
Collapse
|
46
|
Cruz MR, Limentani K, Taxter T, Santa-Maria CA, Behdad A, Gradishar WJ, Nagy RJ, Cristofanilli M. Abstract PD4-05: Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd4-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Cyclin D kinase inhibitors (CDK-is) have shown clinical efficacy in estrogen receptor (ER)-positive metastatic breast cancer (MBC) when combined with aromatase inhibition or estrogen receptor (ER) antagonism. Despite the benefit of this approach, clinical resistance develops sometimes early in the treatment without any response to endocrine therapy (primary endocrine resistance) or after initial response (secondary resistance) in all patients in the metastatic setting and the molecular basis for this resistance are still largely unknown. We evaluated the pattern of genomic alterations in circulating cell-free tumor DNA (ctDNA) analysis of metastatic breast cancer patients with ER-positive tumors treated with palbociclib combined with either letrozole or fulvestrant and progressing during therapy.
Methods: We conducted a retrospective study of patients with ER-positive MBC who had longitudinal assessment of their disease by ctDNA analysis. The plasma-based assay was performed utilizing Guardant360 (Guardant Health, CA), a digital NGS technology to sequence a panel of > 50 cancer genes. After tabulating number of genomic alterations detected for every patient at baseline and after CDK-i therapy, analysis was performed to identify molecular profile changes in the entire population and in individuals with early progression of disease (<6 months).
Results: We analyzed data of 15 ER-positive MBC patients: 8 patients received fulvestrant/palbociclib and 7 received letrozol/palpociclib. The most common mutations before CDK-i therapy were: PIK3CA (16%), TP53 (16%), ESR1 (13%), KIT (9%), EGFR (3%), APC (3%), ERBB2 (3%), MYC (3%), PTEN (3%), RB1 (3%). After therapy with CDK-i the pattern of mutations showed stable and persistent incidence of PIK3CA, TP53 and ESR1. However, new mutations where identified: FGFR1 (6%), IDH (2%), BRCA1 (2%), BRCA2 (2%), CCNE (2%), CCND1 (2%), RAF (2%), AR (2%), ALK(2%). Also, the pattern of gene amplifications presented an increased rate of MYC and FGFR1 amp. Patients with progression of disease before 6 months of CDK-i therapy presented baseline higher number and variation of mutations compared to patients with disease controlled beyond 6 months of therapy.
Conclusion: Longitudinal assessment with ctDNA analysis suggest that a genomic alteration landscape consisting of persistent detection of driver and acquired mutations along with emergent new abnormalities in regulatory genes could potentially be related to primary or secondary resistance to CDK-Is in ER+ MBC patients. Future investigation of these alterations should be conducted.
Citation Format: Cruz MR, Limentani K, Taxter T, Santa-Maria CA, Behdad A, Gradishar WJ, Nagy RJ, Cristofanilli M. Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD4-05.
Collapse
Affiliation(s)
- MR Cruz
- Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Thomas Jefferson University Hospital, Philadelphia, PA; Guardant Health, Inc, Redwood City, CA
| | - K Limentani
- Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Thomas Jefferson University Hospital, Philadelphia, PA; Guardant Health, Inc, Redwood City, CA
| | - T Taxter
- Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Thomas Jefferson University Hospital, Philadelphia, PA; Guardant Health, Inc, Redwood City, CA
| | - CA Santa-Maria
- Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Thomas Jefferson University Hospital, Philadelphia, PA; Guardant Health, Inc, Redwood City, CA
| | - A Behdad
- Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Thomas Jefferson University Hospital, Philadelphia, PA; Guardant Health, Inc, Redwood City, CA
| | - WJ Gradishar
- Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Thomas Jefferson University Hospital, Philadelphia, PA; Guardant Health, Inc, Redwood City, CA
| | - RJ Nagy
- Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Thomas Jefferson University Hospital, Philadelphia, PA; Guardant Health, Inc, Redwood City, CA
| | - M Cristofanilli
- Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Thomas Jefferson University Hospital, Philadelphia, PA; Guardant Health, Inc, Redwood City, CA
| |
Collapse
|
47
|
Davis AA, Zhang Y, Behdad A, Taxter T, Strickland K, Santa-Maria C, Flaum L, Cruz MR, Platanias LC, Gradishar WJ, Cristofanilli M. Abstract P2-02-21: The utility and correlation of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) based on HER2 positivity. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-02-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
CTCs are well-established prognostic and predictive biomarkers for metastatic breast cancer (MBC) and other solid tumors. ctDNA is emerging as a quantitative blood-based biomarker for monitoring genomic alterations and disease progression. We evaluated the clinical utility and correlation of these liquid biopsy molecular tools in a cohort of MBC patients.
Methods:
CTC samples were obtained from an ongoing, prospective study of blood based prognostic biomarkers for breast cancer patients. At this time, 71 patients and 98 total samples have been collected. CTC enumeration was performed using the CellSearchTM platform (Menarini, IT). Within this cohort, MBC patients who had ctDNA testing were identified. ctDNA testing was performed using Guardant360TM (Guardant Health, CA), a digital next-generation sequencing technology. Two groups were analyzed: (1) HER2-negative patients with CTC ≥ 5 in 7.5 ml of blood (2) HER2-positive patients who had been treated with HER2 targeted therapy.
Results:
22 samples (N=16 patients) were found with CTC ≥ 5 (range 8-904) and concurrent ctDNA testing (median timeframe between collection 0 days, range 0-42 days). There was a significant association between number of CTCs and the total number of genomic alterations detected in ctDNA (paired two sample t-test, p=0.012). In addition, CTC enumeration was significantly correlated with somatic alteration burden of the dominant clone (paired two sample t-test, p=0.023). The most common alterations detected in the blood were TP53 (55% of patients, 18 total mutations), PIK3CA (41% of patients, 15 total mutations), and ESR1 (32% of patients, 14 total mutations). For patients with HER2 positivity receiving HER2-targeted therapies (N=16 samples from 11 patients), only 18.8% of samples had detectable CTCs (all less than 5) as compared to 75.0% of samples with detectable ctDNA alterations. In N=12 samples with detectable ctDNA mutations, mean number of genomic alterations was 4.4 with mean somatic mutation burden of 2.95%.
CTCs detectedctDNA detectedCTC ≥ 5Mean number of ctDNA alterations+Mean somatic alteration burden+HER2- (only cases with CTC ≥ 5)100% (22/22)100% (22/22)100%6.716.1%HER2+ (all cases)18.8% (3/16)75.0% (12/16)0%4.42.95%+excludes ctDNA samples without detected genomic alterations
Conclusions:
In HER2-negative MBC patients, CTC enumeration was significantly correlated with the number of ctDNA genomic alterations and somatic alteration burden, indicating the potential for ctDNA as a prognostic, quantitative biomarker of tumor burden. In patients with HER2 positivity, ctDNA may be a more sensitive liquid biopsy tool given the rarity of detecting CTCs detection in this population using the CellSearchTM system. In HER2-positive patients, consideration of size-dependent selection of CTCs using filtration of cells that have undergone epithelial-mesenchymal transition may improve detection in this subgroup.
Citation Format: Davis AA, Zhang Y, Behdad A, Taxter T, Strickland K, Santa-Maria C, Flaum L, Cruz MR, Platanias LC, Gradishar WJ, Cristofanilli M. The utility and correlation of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) based on HER2 positivity [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-02-21.
Collapse
Affiliation(s)
- AA Davis
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - Y Zhang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - A Behdad
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - T Taxter
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - K Strickland
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - C Santa-Maria
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - L Flaum
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - MR Cruz
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - LC Platanias
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - WJ Gradishar
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - M Cristofanilli
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
48
|
Formisano L, Lu Y, Jansen VM, Bauer JA, Hanker A, Gonzalez Ericsson P, Lee KM, Nixon MJ, Guerrero-Zotano AL, Schwarz LJ, Sanders M, Sudhan D, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Mayer IA, Arteaga CL. Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs6-05] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CDK4/6 inhibitors have been approved in combination with endocrine therapy for treatment of ER+ metastatic breast cancer. The goal of this study was to discover mechanisms of resistance to ER antagonists alone and in combination with CDK4/6 inhibitors.
Results: To achieve this goal, we used lentiviral vectors to individually express 559 human kinase open reading frames (ORFs) in ER+ MCF7 human breast cancer cells treated with fulvestrant ± the CDK4/6 inhibitor ribociclib. In MCF7 cells treated with fulvestrant alone or with ribociclib, we identified 15 and 17 kinases associated with resistance, respectively. Ten of these kinases overlapped in both groups. In a secondary screen, MCF7 cells were stably transduced with V5-tagged lentiviruses expressing the positive 'hits' for treatment with fulvestrant/ribociclib. Five of 17 kinases (FGFR1, FRK, HCK, FGR, CRKL) were confirmed to induce resistance to fulvestrant/palbociclib and fulvestrant/ribociblib. Survey of TCGA for copy number alterations and/or expression of these 5 genes showed only FGFR1 to be amplified/overexpressed in ˜15% of ER+ breast cancers. Experiments in vitro showed that ER+/FGFR1-amplified (amp) MDA-134, CAMA-1 and HCC1500 human breast cancer cells and MCF7 cells stably transduced with FGFR1 were relatively resistant to estrogen deprivation, fulvestrant and fulvestrant/palbociclib compared to non-FGFR1 amp MCF7 cells. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Treatment with fulvestrant or palbociclib alone modestly delayed growth of ER+/FGFR1-amp breast cancer patient-derived xenografts (PDX) established in nude mice. However, addition of the FGFR TKI erdafitinib to fulvestrant/palbociclib resulted in marked PDX regression in all mice without associated toxicity and a complete cell cycle arrest measured by Ki67. Treatment of FGFR-amp cells with FGF-2 strongly induced CCND1 (cyclin D1) expression. Downregulation of CCND1 with CCND1 RNAi oligonucleotides restored sensitivity of FGFR1-amp cells to fulvestrant/palbociclib, thus phenocopying the effect of FGFR TKIs. Conversely, overexpression of CCND1 in MCF7 cells induced resistance to estrogen deprivation and to fulvestrant ± palbociclib. Finally, we examined next gen sequencing of cell free tumor DNA by Guardant360 in 34 patients before and after progression on CDK4/6 inhibitor. In 10/34 (29%) post-progression specimens, we detected alterations in the FGFR pathway: FGFR1 amplification (n=7), FGFR1 N546K (n=1), FGFR2 N549K (n=1), and FGFR2 V395D (n=1) activating mutations.
Conclusions: These data suggest aberrant FGFR signaling is a mechanism of resistance to anti-ER therapies ± CDK4/6 inhibitors. We posit overexpression of cyclin D1 induced by both FGFR signaling and ER transcription plays a role in drug resistance. Based on these findings we propose ER+/FGFR1 amplified breast cancers are endocrine resistant and should be candidates for treatment with combinations of ER and FGFR antagonists. Accordingly, we have initiated a phase Ib trial of fulvestrant, palbociclib and erdafitinib in patients with antiestrogen resistant ER+/HER2-negative breast cancer with FGFR1-4 amplification.
Citation Format: Formisano L, Lu Y, Jansen VM, Bauer JA, Hanker A, Gonzalez Ericsson P, Lee K-M, Nixon MJ, Guerrero-Zotano AL, Schwarz LJ, Sanders M, Sudhan D, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Mayer IA, Arteaga CL. Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS6-05.
Collapse
Affiliation(s)
- L Formisano
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - Y Lu
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - VM Jansen
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - JA Bauer
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - A Hanker
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - P Gonzalez Ericsson
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - K-M Lee
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - MJ Nixon
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - AL Guerrero-Zotano
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - LJ Schwarz
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - M Sanders
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - D Sudhan
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - TC Dugger
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - MR Cruz
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - A Behdad
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - M Cristofanilli
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - A Bardia
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - J O'Shaughnessy
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - IA Mayer
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| | - CL Arteaga
- Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center
| |
Collapse
|
49
|
Towner RA, Saunders D, Smith N, Towler W, Cruz M, Do S, Maher JE, Whitaker K, Lerner M, Morton KA. Assessing long-term neuroinflammatory responses to encephalopathy using MRI approaches in a rat endotoxemia model. GeroScience 2018; 40:49-60. [PMID: 29417380 PMCID: PMC5832664 DOI: 10.1007/s11357-018-0009-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 01/30/2018] [Indexed: 02/08/2023] Open
Abstract
Sepsis-associated encephalopathy (SAE) induces neuroinflammation, which is associated with cognitive impairment (CI). CI is also correlated with aging. We used contrast-enhanced magnetic resonance imaging (MRI), perfusion MRI, and MR spectroscopy to assess long-term alterations in BBB permeability, microvascularity, and metabolism, respectively, in a rat lipopolysaccharide-induced SAE model. Free radical-targeted molecular MRI was used to detect brain radical levels at 24 h and 1 week post-LPS injection. CE-MRI showed increased Gd-DTPA uptake in LPS rat brains at 24 h in cerebral cortex, hippocampus, thalamus, and perirhinal cortex regions. Increased MRI signal intensities were observed in LPS rat brains in cerebral cortex, perirhinal cortex, and hippocampus regions 1 week post-LPS. Long-term BBB dysfunction was detected in the cerebral cortex at 6 weeks post-LPS. Increased relative cerebral blood flow (rCBF) in cortex and thalamus regions at 24 h, decreased cortical and hippocampal rCBF at 6 weeks, decreased cortical rCBF at 3 and 12 weeks, and increased thalamus rCBF at 6 weeks post-LPS, were detected. MRS indicated that LPS-exposed rat brains had decreased: NAA/Cho metabolite ratios at 1, 3, 6, and 12 weeks; Cr/Cho at 1, 3, and 12 weeks; and Myo-Ins/Cho at 1, 3, and 6 weeks post-LPS. Free radical imaging detected increased radical levels in LPS rat brains at 24 h and 1 week post-LPS. LPS-exposed rats were compared to saline-treated controls. We clearly demonstrated BBB dysfunction, impaired vascularity, and decreased brain metabolites, as measures of long-term neuroinflammatory indicators, as well as increased free radicals in a LPS-induced rat SAE model.
Collapse
Affiliation(s)
- Rheal A Towner
- Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK, 73104, USA.
- Oklahoma Nathan Shock Aging Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
- Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
| | - D Saunders
- Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK, 73104, USA
| | - N Smith
- Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK, 73104, USA
| | - W Towler
- Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK, 73104, USA
| | - M Cruz
- Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK, 73104, USA
| | - S Do
- Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK, 73104, USA
| | - J E Maher
- Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK, 73104, USA
| | - K Whitaker
- Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK, 73104, USA
| | - M Lerner
- Department of Surgery Research Laboratory, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - K A Morton
- Department of Radiology and Imaging Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA
| |
Collapse
|
50
|
Hernandez-Martínez A, Lujan-Montelongo J, Silva-Cuevas C, Mota-Morales JD, Cortez-Valadez M, Ruíz-Baltazar ÁDJ, Cruz M, Herrera-Ordonez J. Swelling and methylene blue adsorption of poly(N,N-dimethylacrylamide-co-2-hydroxyethyl methacrylate) hydrogel. REACT FUNCT POLYM 2018. [DOI: 10.1016/j.reactfunctpolym.2017.11.008] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|